

Objection Deadline: November 8, 2021 at 12:00 p.m. (Prevailing Eastern Time)

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., *et al.*,

Debtors. ¹**

Chapter 11

Case No. 19-23649

(Jointly Administered)

**NOTICE OF TWENTY-THIRD MONTHLY STATEMENT OF
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE DEBTORS
FOR THE PERIOD FROM AUGUST 1, 2021 THROUGH AUGUST 31, 2021**

Name of Applicant:	Skadden, Arps, Slate, Meagher & Flom LLP
Authorized to Provide Services to:	Purdue Pharma L.P., <i>et al.</i>
Date of Retention:	November 25, 2019, <i>nunc pro tunc</i> to September 15, 2019
Period for Which Compensation and Expense Reimbursement is Sought:	August 1, 2021 through August 31, 2021
Amount of Compensation Requested:	\$887,427.90
Less 20% Holdback:	\$177,485.58
Net of Holdback:	\$709,942.32
Amount of Expense Reimbursement Requested:	\$30,031.30
Total Compensation (Net of Holdback) and Expense Reimbursement Requested:	\$739,973.62

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P., Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

In accordance with the Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**”),² Skadden, Arps, Slate, Meagher & Flom LLP (“**Skadden**”) hereby submits this Twenty-Third monthly statement (the “**Twenty-Third Monthly Statement**”), seeking compensation for services rendered and reimbursement of expenses incurred as special counsel to the Debtors, for the period from August 1, 2021 through August 31, 2021 (the “**Twenty-Third Monthly Period**”). By this Twenty-Third Monthly Statement, and after taking into account certain voluntary discounts and reductions,³ Skadden seeks payment in the amount of \$739,973.62 which comprises (i) 80% of the total amount of compensation sought for actual and necessary services rendered during the Twenty-Third Monthly Period and (ii) reimbursement of 100% of actual and necessary expenses incurred in connection with such services.

SERVICES RENDERED AND EXPENSES INCURRED

1. Attached hereto as **Exhibit A** is a summary of Skadden professionals by individual, setting forth the (a) name and title of each individual who provided services for the Twenty-Third Monthly Period, (b) aggregate hours spent by each individual, (c) hourly billing rate for each such individual at Skadden’s then-current billing rates, (d) amount of fees earned by each Skadden professional, and (e) year of bar admission for each attorney. The blended hourly

² Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Interim Compensation Order.

³ In addition to the volume discount, the total amount sought for fees and expenses (\$917,459.20) reflects voluntary reductions for this period of \$2,691.00 in fees and \$983.12 in expenses, for an overall voluntary reduction of 0.36%. Skadden reserves the right to request these amounts.

(cont’d)

billing rate of Skadden timekeepers during the Twenty-Third Monthly Period is approximately \$1,268.53⁴

2. Attached hereto as **Exhibit B** is a summary of the services rendered and compensation sought, by project category, for the Twenty-Third Monthly Period.

3. Attached hereto as **Exhibit C** is a summary of expenses incurred and reimbursement sought, by expense type, for the Twenty-Third Monthly Period.

4. Attached hereto as **Exhibit D** is itemized time records of Skadden professionals for the Twenty-Third Monthly Period and summary materials related thereto.

5. Attached hereto as **Exhibit E** is an itemized record of certain expenses for the Twenty-Third Monthly Period.

NOTICE AND OBJECTION PROCEDURES

6. Notice of this Twenty-Third Monthly Statement shall be given by hand or overnight delivery upon the following parties (the “**Application Recipients**”): (i) Purdue Pharma L.P., 201 Tresser Blvd, Stamford, CT 06901, Attn.: Jon Lowne, Email: Jon.Lowne@pharma.com; (ii) counsel to the Debtors, Davis Polk & Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, Attn.: Christopher Robertson and Dylan Consla, Email: christopher.robertson@davispolk.com, dylan.consla@davispolk.com; (iii) counsel to the Committee: (a) Akin Gump Strauss Hauer & Feld LLP, One Bryant Park, Bank of America Tower, New York, New York 10036-6745, Attn.: Arik Preis and Sara L. Brauner, Email: apreis@akingump.com and sbrauner@akingump.com; and (b) Bayard, P.A., 600 N. King Street, Suite 400, Wilmington, DE 19801, Attn.: Justin R. Alberto and Daniel N. Brogan, Email:

⁴ The blended rate is comprised of all Skadden timekeepers who provided services during the Twenty-Third Monthly Period.

jalberto@bayardlaw.com and dbrogan@bayardlaw.com; and (iv) the Office of the United States Trustee, U.S. Federal Office Building, 201 Varick Street, Suite 1006, New York, New York 10014, Attn.: Paul K. Schwartzberg, Email: Paul.Schwartzberg@usdoj.gov. (collectively, the “**Notice Parties**”).

7. Objections to this Twenty-Third Monthly Statement, if any, must be served upon the Notice Parties, and by email, hand, or overnight delivery upon Skadden, Arps, Slate, Meagher & Flom LLP, 1440 New York Avenue NW, Washington, D.C. 20005, Attn.: Jennifer Bragg, Email: Jennifer.Bragg@skadden.com, 155 North Wacker Drive, Chicago, Illinois 60606, Attn.: Patrick Fitzgerald, Email: Patrick.Fitzgerald@skadden.com, One Rodney Square, 920 N. King Street, Wilmington, Delaware 19801, Attn.: Anthony W. Clark, Email: Anthony.Clark@skadden.com, and 525 University Avenue, Palo Alto, California, 94301, Attn.: Jennifer Madden, Email: Jennifer.Madden@skadden.com no later than November 8, 2021 at 12:00 p.m. (Prevailing Eastern Time) (the “**Objection Deadline**”), setting forth the nature of the objection and the specific amount of fees or expenses at issue.

8. If no objections to this Twenty-Third Monthly Statement are received by the Objection Deadline, the Debtors shall promptly pay Skadden 80% of the fees and 100% of the expenses identified in this Twenty-Third Monthly Statement.

9. To the extent that an objection to this Twenty-Third Monthly Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Twenty-Third Monthly Statement to which the objection is directed and promptly pay the remainder of the fees and expenses in the percentages set forth above. To the extent such objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing.

Dated: October 25, 2021

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

/s/ Julie E. Cohen

Julie E. Cohen
One Manhattan West
New York, New York 10001
Telephone: (212) 735-3000
Fax: (212) 735-2000

– and –

Patrick Fitzgerald
155 North Wacker Drive
Chicago, Illinois 60606-1720
Telephone: (312) 407-0700
Fax: (312) 407-0411

– and –

Jennifer L. Bragg
1440 New York Avenue, N.W.
Washington, D.C. 20005
Telephone: (202) 371-7000
Fax: (202) 393-5760

*Special Counsel to Debtors
and Debtors-in-Possession*

EXHIBIT A

**SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
PROFESSIONAL PERSON SUMMARY
AUGUST 1, 2021 – AUGUST 31, 2021**

<u>NAME</u>	<u>YEAR OF ADMISSION</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
<u>PARTNER</u>				
Jennifer L. Bragg	1996	1,565.00	150.10	\$ 234,906.50
Anthony W. Clark	1979	1,565.00	16.10	25,196.50
Elena M. Coyle	2011	1,275.00	1.20	1,530.00
Patrick Fitzgerald	1986	1,775.00	60.10	106,677.50
Maya P. Florence	2004	1,425.00	115.60	164,730.00
Marie L. Gibson	1997	1,565.00	2.80	4,382.00
William (Bill) McConagha	1993	1,275.00	97.80	124,695.00
William Ridgway	2006	1,425.00	25.50	36,337.50
Resa K. Schlossberg	2005	1,425.00	3.00	4,275.00
TOTAL PARTNER			472.20	\$ 702,730.00
<u>OF COUNSEL</u>				
Karen C. Corallo	1984	1,175.00	4.00	\$ 4,700.00
TOTAL OF COUNSEL			4.00	\$ 4,700.00
<u>COUNSEL</u>				
Michael S. Bailey	2007	1,260.00	0.50	\$ 630.00
John Boyle	1996	1,260.00	6.30	7,938.00
Avia M. Dunn	2008	1,260.00	58.80	74,088.00
TOTAL COUNSEL			65.60	\$ 82,656.00
<u>ASSOCIATE</u>				
William A. Bejan	2018	825.00	6.60	\$ 5,445.00
Jennifer H. Berman	2014	1,120.00	2.90	3,248.00
Elizabeth L. Berry	2016	995.00	11.00	10,945.00
Amanda H. Chan	2019	825.00	60.10	49,582.50
Barri Dean	2019	825.00	12.00	9,900.00
Emily Hellman	2017	995.00	47.70	47,461.50
Corbin D. Houston	2017	940.00	26.50	24,910.00
Kendall R. Ickes	2020	695.00	16.00	11,120.00
Julie Lee	2014	1,120.00	1.40	1,568.00
Jennifer Madden	2010	1,120.00	6.50	7,280.00
William S. O'Hare	2013	1,120.00	0.80	896.00
Sterling M. Paulson	2018	825.00	5.40	4,455.00

Catherine Yuh	2020	695.00	7.20	5,004.00
		TOTAL ASSOCIATE	204.10	\$ 181,815.00
<u>PARAPROFESSIONALS</u>				
William R. Fieberg	N/A	450.00	4.90	\$ 2,205.00
Michael J. Hohmann	N/A	450.00	9.50	4,275.00
Rachel Redman	N/A	450.00	17.00	7,650.00
		TOTAL PARAPROFESSIONALS	31.40	\$ 14,130.00
		TOTAL	777.30	\$ 986,031.00
		VOLUME DISCOUNT		\$ 98,603.10
		TOTAL FEES		\$ 887,427.90
BLENDED HOURLY RATE \$1,268.53				

EXHIBIT B

**COMPENSATION BY PROJECT CATEGORY
(AUGUST 1, 2021 – AUGUST 31, 2021)**

Project Category	Total Hours	Total Fees
Bankruptcy Emergence Process	151.80	\$177,840.50
Bankruptcy Related Litigation and Regulation	225.10	304,859.00
Compliance Project	15.80	23,401.00
Corporate/Transactional Matter	96.50	115,142.50
DOJ	123.10	179,861.50
General Advice	18.70	28,119.00
General Compliance	6.20	8,382.50
Healthcare Law Compliance	34.20	34,305.00
Litigation Discovery Issues	15.10	19,397.50
Managed Care Review	6.00	8,147.00
Project Catalyst	17.10	16,375.50
Project Chimera	1.30	1,049.50
Retention/Fee Matter	37.70	46,677.50
Rhodes Companies	5.40	6,885.00
Various Texas Actions	23.30	15,588.00
TOTAL	777.30	\$ 986,031.00
VOLUME DISCOUNT		\$ 98,603.10
TOTAL FEES		\$ 887,427.90

EXHIBIT C

**SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
EXPENSE SUMMARY
(AUGUST 1, 2021 – AUGUST 31, 2021)**

Expense Category	Total Expenses
Secondment of Skadden Attorney	\$ 30,000.00
Courier & Express Carriers (e.g., Federal Express)	31.30
TOTAL	\$ 30,031.30

EXHIBIT D

TIME DETAIL

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
Bankruptcy Emergence Process

Bill Date: 10/15/21
Bill Number: 1869051

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/03/21	3.40	PREPARE FOR AND ATTEND CALL RE: PR LICENSING ISSUES (1.0); CONFER WITH CLIENT RE: CHANGE OF CONTROL AND LICENSING ISSUES (0.9); REVIEW AND ANALYSIS OF CHANGE OF CONTROL ISSUES (1.5).
BRAGG JL	08/04/21	2.20	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.7); CONFER WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.9); CONFER WITH CO-COUNSEL RE: LICENSING ISSUES (0.6).
BRAGG JL	08/05/21	1.10	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.4); CONFER WITH CO-COUNSEL RE: LICENSING ISSUES (0.7).
BRAGG JL	08/11/21	0.60	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.6).
BRAGG JL	08/12/21	0.70	CONFER WITH CO-COUNSEL RE: MEETING AND PREP (0.7).
BRAGG JL	08/13/21	2.40	PREPARE FOR CALL WITH FDA RE: CHANGE OF CONTROL ISSUES (1.3); CALL WITH FDA RE: CHANGE OF CONTROL ISSUES (1.1).
BRAGG JL	08/17/21	1.50	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.5); CALL WITH CLIENT TO DISCUSS CHANGE OF CONTROL ISSUES (1.0).
BRAGG JL	08/18/21	2.50	CONFER WITH CO-COUNSEL RE: LICENSING ISSUES (0.8); REVIEW AND EDIT SUBMISSION (1.7).
BRAGG JL	08/20/21	2.30	CONFER WITH CLIENT RE: CHANGE OF CONTROL OFFICER ISSUES (1.0); CONFER WITH CLIENT RE: EMERGENCE PLANNING ISSUE (1.3).
BRAGG JL	08/23/21	2.40	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUE (0.6); CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.4); CALL WITH CLIENT RE: CHANGE OF CONTROL ISSUES (0.6); CONFER WITH CLIENT RE: BANKRUPTCY EMERGENCE ISSUES (0.8).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BRAGG JL	08/24/21	0.50	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.5).
BRAGG JL	08/25/21	1.00	CONFER WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (1.0).
BRAGG JL	08/26/21	1.10	CONFER WITH CO-COUNSEL RE: AGREEMENTS (0.5); CONDUCT RESEARCH RE: AGREEMENTS (0.6).
BRAGG JL	08/27/21	2.80	CALL WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (1.2); STRATEGY CALL WITH CLIENT RE: CHANGE OF CONTROL ISSUES (1.0); REVIEW AND EDIT REGULATORY CORRESPONDENCE (0.6).
BRAGG JL	08/30/21	1.50	REVIEW REGULATORY CORRESPONDENCE RE: CHANGE OF CONTROL ISSUES (0.3); CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.7); CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.5).
BRAGG JL	08/31/21	0.80	CONFER WITH CO- COUNSEL RE: CHANGE OF CONTROL ISSUES (0.8).
		26.80	
FLORENCE MP	08/02/21	0.80	CONFER WITH CLIENT AND CO-COUNSEL RE: (0.3); REVISE DRAFT TALKING POINTS RE: CHANGE OF CONTROL ISSUES (0.5).
FLORENCE MP	08/03/21	1.60	PREPARE FOR AND PARTICIPATE IN CALL WITH CLIENT RE: LICENSING ISSUES (1.2); CORRESPOND WITH CONSULTANT AND SKADDEN TEAM RE: LICENSING ISSUES (0.4).
FLORENCE MP	08/04/21	0.90	CORRESPOND WITH CLIENT AND CONSULTANT RE: CHANGE OF CONTROL PROCESS (0.4); CONFER J. BRAGG AND W. MCCONAGHA RE: SAME (0.5).
FLORENCE MP	08/05/21	0.30	CORRESPOND WITH CLIENT AND CONSULTANT RE: CHANGE OF CONTROL PROCESS (0.3).
FLORENCE MP	08/06/21	0.40	CORRESPOND WITH CLIENT AND SKADDEN TEAM RE: CHANGE OF CONTROL PROCESS (0.4).
FLORENCE MP	08/10/21	0.80	CONFER WITH A. DUNN RE: LICENSING ISSUES AND REVIEW MATERIALS RE: SAME (0.2); CORRESPOND WITH CLIENT RE: SAME (0.3); CONFER WITH W. MCCONAGHA RE: CHANGE OF CONTROL PROCESS (0.1); CONFER WITH CLIENT RE: SAME (0.2).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/11/21	2.30	CORRESPOND WITH CO-COUNSEL RE: LICENSING ISSUES (1.0); CONFER WITH CLIENT TEAM AND A. DUNN RE: SAME (0.9); CORRESPOND WITH SKADDEN TEAM AND CLIENT RE: CHANGE OF CONTROL (0.2); CORRESPOND WITH W. MCCONAGHA RE: CHANGE OF CONTROL ISSUES (0.1); CORRESPOND WITH W. MCCONAGHA AND A. CHAN RE: CHANGE OF CONTROL ISSUES (0.1).
FLORENCE MP	08/12/21	1.10	CORRESPOND WITH A. DUNN RE: LICENSING (0.1); CORRESPOND WITH W. MCCONAGHA RE: CHANGE OF CONTROL ISSUES (0.1); CORRESPOND WITH CLIENT RE: CHANGE OF CONTROL ISSUES (0.5); CONFER WITH A. CHAN AND W. MCCONAGHA RE: CHANGE OF CONTROL ISSUES (0.4).
FLORENCE MP	08/13/21	3.00	REVIEW AND COMMENT ON LICENSE ANALYSIS (0.3); PREPARE FOR AND PARTICIPATE IN CALL WITH FDA RE: REGULATORY ITEMS (1.2); FOLLOW UP WITH BILL MCCONAGHA RE: CALL WITH FDA (0.2); PREPARE FOR CALL WITH CLIENT AND CONSULTANT (0.3) RE: LICENSING ISSUES PARTICIPATE IN CALL RE: SAME (0.8).
FLORENCE MP	08/14/21	0.20	CORRESPOND WITH A. DUNN RE: LICENSING ISSUES (0.2).
FLORENCE MP	08/16/21	1.80	PARTICIPATE IN WEEKLY CALL WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL (0.5); CONFER WITH CLIENT AND CO-COUNSEL RE: LICENSING ISSUES (0.8); ANALYZE SAME AND CONFER WITH A. DUNN RE: ANALYSIS (0.5).
FLORENCE MP	08/17/21	2.00	CONFER WITH J. BRAGG RE: CHANGE OF CONTROL PROCESS (0.1); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.7); FOLLOW UP EMAIL WITH CO-COUNSEL RE: SAME (0.1); TALKING POINTS RE: LICENSING ISSUES (0.8); CORRESPOND WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.3).
FLORENCE MP	08/18/21	1.60	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: LICENSING ISSUES (0.3); CORRESPOND WITH CLIENT AND CONSULTANT RE: CHANGE OF CONTROL PROCESS (0.2); CONFER WITH A. DUNN RE: LICENSING ISSUES (0.2); CORRESPOND WITH CONSULTANT RE: SAME (0.3); REVIEW AND EDIT DRAFT OUTLINE RE: CHANGE OF CONTROL ISSUES (0.6).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/19/21	2.20	CORRESPOND WITH CO-COUNSEL AND CLIENT RE: CHANGE OF CONTROL ISSUE (0.6); CORRESPOND WITH CLIENT RE: SAME (0.2); CONFER WITH E. HELLMAN RE: LICENSING ISSUES (0.4); PARTICIPATE IN CALL WITH CLIENT AND CONSULTANT RE: SAME (1.0).
FLORENCE MP	08/20/21	0.20	CORRESPOND WITH CLIENT RE: CHANGE OF CONTROL ISSUES (0.2).
FLORENCE MP	08/23/21	1.00	CONFER WITH CO-COUNSEL RE: LICENSING ISSUES (0.2); CORRESPOND WITH SKADDEN TEAM RE: CHANGE OF CONTROL PROCESS (0.1); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: SAME (0.2); CONFER WITH SKADDEN TEAM RE: CHANGE OF CONTROL PROCESS (0.5).
FLORENCE MP	08/24/21	0.90	CORRESPOND WITH CO-COUNSEL RE: CHANGE OF CONTROL PROCESS (0.2); CORRESPOND WITH CLIENT RE: SAME (0.7).
FLORENCE MP	08/25/21	1.20	PARTICIPATE IN CALL WITH CLIENT AND CONSULTANT RE: LICENSING ISSUES (1.0); CORRESPOND WITH CLIENT AND SKADDEN TEAM RE: SAME (0.2).
FLORENCE MP	08/26/21	2.50	CORRESPOND WITH CONSULTANT RE: LICENSING ISSUES (0.2); CORRESPOND WITH CLIENT RE: SAME (0.4); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.1); CONFER WITH CLIENT RE: SAME (0.6); CONFER WITH A. DUNN RE: SAME (0.2); REVIEW AND COMMENT ON DRAFT FDA CORRESPONDENCE (0.2); CORRESPOND WITH SKADDEN TEAM RE: CHANGE OF CONTROL ISSUES (0.1); CONFER WITH J. BRAGG RE: CHANGE OF CONTROL ISSUE (0.5); CONFER WITH W. MCCONAGHA RE: SAME (0.2).
FLORENCE MP	08/27/21	1.80	CORRESPOND WITH SKADDEN TEAM RE: LICENSING ISSUES (0.2); PARTICIPATE IN CALL WITH CLIENT TEAM AND SKADDEN RE: CHANGE OF CONTROL ISSUES (0.6); CONFER WITH CLIENT, J. BRAGG AND W. MCCONAGHA RE: SAME (0.5); CONFER WITH J. BRAGG RE: CHANGE OF CONTROL PROCESS (0.5).
FLORENCE MP	08/30/21	0.50	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL PROCESS (0.5).
FLORENCE MP	08/31/21	0.30	CORRESPOND WITH CO-COUNSEL RE: LICENSING ISSUES (0.3).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

27.40

SCHLOSSBERG RK	08/27/21	0.30	CONFER WITH SKADDEN TEAM MEMBERS RE: MATTER (0.3).
----------------	----------	------	--

0.30

Total Partner

54.50

CORALLO KC	08/31/21	4.00	RESEARCH AND REVISE AGREEMENT (3.0); CORRESPOND WITH SKADDEN TEAM RE: SAME (1.0).
------------	----------	------	---

4.00

Total Of Counsel

4.00

DUNN AM	08/02/21	1.00	REVIEW EMAILS RE: LICENSING ISSUES (1.0).
---------	----------	------	---

DUNN AM	08/03/21	2.20	PARTICIPATE ON CALLS RE: LICENSING ISSUES (2.2).
---------	----------	------	--

DUNN AM	08/04/21	1.10	REVIEW AND RESPOND TO CORRESPONDENCE RE: LICENSING ISSUES (1.1).
---------	----------	------	--

DUNN AM	08/06/21	1.80	REVIEW AND RESPOND TO CORRESPONDENCE RE: LICENSING ISSUES (1.8).
---------	----------	------	--

DUNN AM	08/06/21	1.00	PARTICIPATE ON CALL RE: LICENSING ISSUES (1.0).
---------	----------	------	---

DUNN AM	08/09/21	1.10	REVIEW MATERIAL RE: LICENSING ISSUES (1.1).
---------	----------	------	---

DUNN AM	08/10/21	1.10	ADDRESS ISSUES RE: LICENSING; DRAFT CHART RE: SAME (1.1).
---------	----------	------	---

DUNN AM	08/11/21	0.50	PARTICIPATE ON CALL WITH CLIENT (0.5).
---------	----------	------	--

DUNN AM	08/11/21	3.50	REVIEW AND REVISE MATERIAL RE: CHANGE OF OWNERSHIP (3.5).
---------	----------	------	---

DUNN AM	08/12/21	0.80	PARTICIPATE ON CALL WITH CLIENT RE: LICENSING STRATEGY (0.8).
---------	----------	------	---

DUNN AM	08/12/21	2.90	REVIEW LICENSING CHART (2.9).
---------	----------	------	-------------------------------

DUNN AM	08/13/21	1.20	REVISE ENGAGEMENT LETTER (1.2).
---------	----------	------	---------------------------------

DUNN AM	08/13/21	0.80	PARTICIPATE ON CALL WITH CONSULTANT (0.8).
---------	----------	------	--

DUNN AM	08/13/21	2.20	REVISE MATERIAL RE: LICENSING (2.2).
---------	----------	------	--------------------------------------

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

DUNN AM	08/14/21	2.10	RESPOND TO QUESTIONS RE: LICENSING ISSUES (2.1).
DUNN AM	08/16/21	0.50	PREPARE FOR AND PARTICIPATE ON CALL RE: LICENSING ISSUES (0.5).
DUNN AM	08/16/21	0.80	ADDRESS FOLLOW UPS RE: LICENSING ISSUES (0.8).
DUNN AM	08/18/21	0.80	REVISE LICENSING CHART (0.8).
DUNN AM	08/24/21	4.10	REVIEW AND RESPOND TO QUESTIONS RE: LICENSING ISSUES (4.1).
DUNN AM	08/25/21	1.00	PARTICIPATE ON WEEKLY LICENSING UPDATE CALL (1.0).
DUNN AM	08/26/21	0.90	RESPOND TO LICENSING QUESTIONS (0.9).
DUNN AM	08/27/21	1.10	ATTEND TO LICENSING ISSUES (1.1).
DUNN AM	08/30/21	3.50	ATTEND TO LICENSING ISSUES (3.5).
DUNN AM	08/31/21	0.40	ATTEND TO LICENSING ISSUES (0.4).

36.40**Total Counsel****36.40**

CHAN AH	08/02/21	5.50	DRAFT MEETING TALKING POINTS (5.5).
CHAN AH	08/05/21	0.90	CONFER WITH CLIENT ON NEXT STEPS (0.9).
CHAN AH	08/05/21	0.20	PREPARE FOR CALL (0.2).
CHAN AH	08/09/21	0.20	DISCUSS NEXT STEPS (0.2).
CHAN AH	08/11/21	7.40	REVIEW AGREEMENTS FOR PROVISION OF INTEREST (7.4).
CHAN AH	08/12/21	0.30	CONFER ON NEXT STEPS (0.3).
CHAN AH	08/12/21	2.40	REVIEW AGREEMENTS FOR PROVISION OF INTEREST (2.4).
CHAN AH	08/16/21	3.70	RESEARCH REGULATORY TOPICS (3.7).
CHAN AH	08/17/21	1.60	DRAFT SUMMARY OF CONTRACT REVIEW (1.6).
CHAN AH	08/18/21	0.10	CONFER ON CONTRACT ANALYSIS (0.1).
CHAN AH	08/18/21	1.60	REVIEW CONTRACTS (1.6).
CHAN AH	08/19/21	1.30	REVIEW FORMS FOR PROVISIONS OF INTEREST (1.3).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

CHAN AH	08/23/21	0.30	REVIEW FORMS FOR PROVISION OF INTEREST (0.3).
CHAN AH	08/25/21	1.40	REVISE TALKING POINTS (1.4).
CHAN AH	08/27/21	0.80	CONFER ON NEXT STEPS (0.8).
CHAN AH	08/27/21	0.20	REVIEW MATERIALS FOR CALL ON NEXT STEPS (0.2).
CHAN AH	08/30/21	1.50	REVISE AGREEMENT (1.5).
CHAN AH	08/30/21	0.50	CONDUCT REGULATORY RESEARCH (0.5).
CHAN AH	08/31/21	0.70	REVIEW AGREEMENT (0.7).
CHAN AH	08/31/21	0.30	CONFER ON SCOPE OF RESEARCH (0.3).
CHAN AH	08/31/21	1.90	CONDUCT REGULATORY RESEARCH (1.9).

32.80

HELLMAN E	08/18/21	4.20	CONDUCT RESEARCH RE: REGULATORY QUESTION (4.2).
HELLMAN E	08/19/21	1.00	CONFER WITH TEAM RE: LICENSING ISSUES (1.0).
HELLMAN E	08/19/21	3.90	CONDUCT RESEARCH RE: LICENSING ISSUE (3.9).
HELLMAN E	08/19/21	0.30	CONFER WITH M. FLORENCE RE: LICENSING ISSUES (0.3).
HELLMAN E	08/20/21	4.30	CONDUCT REGULATORY RESEARCH (4.3).
HELLMAN E	08/24/21	0.30	PREPARE FOR TEAM CALL RE: LICENSING QUESTIONS (0.3).
HELLMAN E	08/31/21	0.60	PREPARE FOR TEAM CALL RE: LICENSING ISSUES (0.6).

14.60**Total Associate 47.40**

HOHMANN MJ	08/11/21	3.90	REVISE MATERIALS RE: LICENSING ISSUES (3.9).
HOHMANN MJ	08/12/21	1.90	REVISE MATERIALS RE: LICENSING ISSUES (1.9).
HOHMANN MJ	08/13/21	0.70	REVISE MATERIALS RE: LICENSING ISSUES (0.7).
HOHMANN MJ	08/17/21	2.10	REVISE MATERIALS RE: LICENSING ISSUES (2.1).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

HOHMANN MJ	08/19/21	0.90	ATTEND LICENSING CALL WITH SKADDEN, CLIENT AND CONSULTANT (0.9).
------------	----------	------	---

9.50

Total Legal Assistant	9.50
-----------------------	------

MATTER TOTAL	<u>151.80</u>
--------------	---------------

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.

Bill Date: 10/15/21

Bankruptcy Related Litigation and Regulatory Issues

Bill Number: 1869053

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/01/21	1.80	REVIEW AND EDIT DECLARATION (0.5); CALL WITH CLIENT RE: KERP ISSUES (0.7); CONFER WITH CLIENT RE: BANKRUPTCY RELATED ISSUES (0.6).
BRAGG JL	08/02/21	7.00	REVIEW AND ANALYSIS OF BANKRUPTCY RELATED ISSUES (3.0); CALL WITH DOJ RE: BANKRUPTCY ISSUES (1.5); WORKING SESSION WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUES (2.5).
BRAGG JL	08/03/21	3.30	ATTENTION TO KERP ISSUES (2.0); REVIEW AND EDIT PROPOSED FILINGS (1.3).
BRAGG JL	08/04/21	3.40	CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.5); REVIEW AND ANALYZE BANKRUPTCY MATERIALS (1.3); CONFER WITH CO-COUNSEL RE: EDITS TO PLEADINGS (1.6).
BRAGG JL	08/05/21	4.00	MEETING WITH CO-COUNSEL RE: KERP ISSUES (0.6); STRATEGY SESSION WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUES (1.4); MEETING WITH DOJ AND STATES RE: BANKRUPTCY ISSUES (2.0).
BRAGG JL	08/06/21	3.60	REVIEW AND EDIT BANKRUPTCY MATERIAL (1.4); CALL WITH EXTERNAL PARTY (0.7); REVIEW AND ANALYZE KERP MATERIALS (1.5).
BRAGG JL	08/09/21	2.10	CONFER WITH CO-COUNSEL RE: KERP ISSUES (1.0); CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (1.1).
BRAGG JL	08/10/21	2.00	SPECIAL COMMITTEE MEETING RE: BANKRUPTCY (2.0).
BRAGG JL	08/12/21	1.80	REVIEW MONITOR REPORT (1.1); REVIEW AND ANALYSIS OF KERP ISSUES (0.7).
BRAGG JL	08/13/21	2.40	CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.5); CONFER WITH CO-COUNSEL RE: HEARING ISSUES (0.3); REVIEW AND ANALYZE MONITOR REPORT (0.7); CONFER WITH CO-COUNSEL RE: MONITOR REPORT (0.9).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

BRAGG JL	08/15/21	0.60	REVIEW AND COMMENT ON PLEADINGS (0.6).
BRAGG JL	08/16/21	1.90	CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.5); CONFER WITH CO-COUNSEL AND CLIENT RE: BANKRUPTCY ISSUES (1.4).
BRAGG JL	08/17/21	3.30	CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.6); REVIEW AND ANALYSIS OF KERP ISSUES (0.8); CONFER WITH CLIENT RE: BANKRUPTCY ISSUES (0.5); CONFER WITH CO-COUNSEL RE: CONTRACT ISSUE (0.6); CONFER WITH CO-COUNSEL RE: HEARING RELATED ISSUES (0.8).
BRAGG JL	08/18/21	2.70	CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.9); CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.6); CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (1.2).
BRAGG JL	08/19/21	5.50	CONFER WITH CO-COUNSEL RE: REVIEW OF MATERIALS AS PART OF KERP PROCESS (1.4); CALL WITH CO-COUNSEL RE: STRATEGY AND APPROACH FOR KERP REVIEW (0.5); REVIEW AND ANALYSIS OF KERP ISSUES (0.7); REVIEW AND EDIT PROVISIONS IN MATERIAL RE: BANKRUPTCY (1.5); CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.4); CONFER WITH CO-COUNSEL RE: KERP LETTER (0.5); CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.5).
BRAGG JL	08/20/21	1.50	CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.6); REVIEW AND ANALYZE KEIP FILINGS (0.9).
BRAGG JL	08/21/21	1.50	REVIEW KEIP FILINGS; PREPARE FOR SPECIAL COMMITTEE MEETING (1.5).
BRAGG JL	08/22/21	1.30	PREPARE FOR SPECIAL COMMITTEE MEETING (0.7); CONFER WITH CO-COUNSEL RE: KEIP FILINGS (0.6).
BRAGG JL	08/23/21	2.70	REVIEW AND EDIT BANKRUPTCY MATERIAL (0.7); LISTEN TO DOJ RELATED PORTIONS OF BANKRUPTCY HEARING (1.0); PREPARE FOR SPECIAL COMMITTEE MEETING (1.0).
BRAGG JL	08/24/21	2.60	PREPARE FOR SPECIAL COMMITTEE MEETING (0.6); ATTEND SPECIAL COMMITTEE MEETING (0.5); CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.8); STRATEGY DISCUSSION WITH CO-COUNSEL RE: KERP PROCESS (0.7).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

**ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL**

BRAGG JL	08/25/21	3.90	STRATEGY DISCUSSION WITH CO-COUNSEL RE: KERP ISSUES (1.0); REVIEW AND ANALYZE KERP RELATED MATERIALS (1.5); CALL WITH CO-COUNSEL TO DISCUSS KERP ISSUES (0.5); REVIEW AND EDIT ANALYSIS OF KERP WORK PRODUCT (0.9).
BRAGG JL	08/26/21	0.90	ATTENTION TO KERP ISSUES (0.9).
BRAGG JL	08/27/21	4.30	CONFER WITH CO-COUNSEL RE: KERP ISSUES (1.6); REVIEW AND ANALYZE KERP ISSUES (2.0); CALL WITH CO-COUNSEL RE: KERP REVIEW (0.7).
BRAGG JL	08/30/21	3.60	CONFER WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUE (1.2); CONFER WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.4); ATTENTION TO REVIEW OF DOCUMENTS IN CONNECTION WITH KERP REVIEW (2.0).
BRAGG JL	08/31/21	2.80	CONFER WITH CO-COUNSEL RE: KERP ISSUES (1.5); REVIEW AND ANALYSIS OF KERP ISSUES (1.3).
		70.50	
FITZGERALD P	08/01/21	0.70	UPDATE CALL WITH CLIENT, OUTSIDE COUNSEL AND SKADDEN TEAM RE: REVIEW PROCESS (0.7).
FITZGERALD P	08/05/21	0.50	CALL TO OUTLINE KERP PROCESS (0.5).
FITZGERALD P	08/09/21	1.00	INTERNAL UPDATE CALL RE: PROCESS (0.3); REVIEW CHART (0.5); DRAFT AND SEND EMAIL TO OUTSIDE COUNSEL RE: PROCESS (0.2).
FITZGERALD P	08/10/21	1.40	PARTICIPATE IN SPECIAL COMMITTEE MEETING (1.4).
FITZGERALD P	08/13/21	1.40	GATHER AND REVIEW RELEVANT MATERIALS (1.4).
FITZGERALD P	08/17/21	0.50	INTERNAL UPDATE/ORGANIZATIONAL CALL RE: ANALYSIS (0.5).
FITZGERALD P	08/18/21	0.30	REVIEW UPDATES ON PROGRESS (0.3).
FITZGERALD P	08/19/21	0.90	INTERNAL SKADDEN UPDATE (0.5); RESPOND TO CLIENT INQUIRIES (0.4).
FITZGERALD P	08/20/21	1.10	CONFER WITH SKADDEN TEAM AND CO-COUNSEL RE: REVIEW PROCESS (0.5); SKADDEN UPDATE CALL RE: REVIEW PROCESS (0.6).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	08/21/21	1.30	ATTENTION TO FACT GATHERING PROCESS RE: KERP (1.3).
FITZGERALD P	08/22/21	1.20	CALL WITH OUTSIDE COUNSEL RE:: MOTION (0.9); EDIT PRESENTATION (0.1); REVIEW MATERIALS (0.2).
FITZGERALD P	08/23/21	1.00	CONFER WITH CO-COUNSEL AND SKADDEN TEAM (0.5); PREP FOR SPECIAL COMMITTEE MEETING (0.3); EDIT MATERIAL FOR SPECIAL COMMITTEE MEETING (0.2).
FITZGERALD P	08/24/21	2.60	PREP FOR SPECIAL COMMITTEE MEETING (0.3); PARTICIPATE IN SPECIAL COMMITTEE MEETING (0.6); WORK ON REVIEW PROCESS (0.6); CALL WITH OUTSIDE COUNSEL RE: PROCESS (0.6); CALL WITH CO-COUNSEL (0.4); CONFER WITH J. BRAGG RE: UPDATE (0.1).
FITZGERALD P	08/25/21	2.40	SKADDEN UPDATE AND ORGANIZATION RE: WORKFLOW (1.1); WORK ON KERP REVIEW (1.3).
FITZGERALD P	08/26/21	0.20	ATTENTION TO WORKSTREAM (0.2).
FITZGERALD P	08/27/21	0.90	ATTENTION TO REVIEW ISSUES (0.9).
FITZGERALD P	08/31/21	0.50	UPDATE CALL (0.5).

17.90

FLORENCE MP	08/01/21	1.40	PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY MOTION (0.7); CONFER WITH J. BRAGG RE: SAME (0.2); REVIEW MATERIALS RE: BANKRUPTCY REPOSITORY (0.5).
FLORENCE MP	08/02/21	4.20	PARTICIPATE IN CONFERENCE CALLS WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUE (2.2); REVIEW BANKRUPTCY MATERIAL MARKUPS (0.6); CONFER WITH CO-COUNSEL RE: BANKRUPTCY REPOSITORY (0.8); CORRESPOND WITH SKADDEN TEAM AND CO-COUNSEL RE: KERP PROCESS (0.6).
FLORENCE MP	08/03/21	0.80	PREPARE FOR AND PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: KERP PROCESS (0.8).
FLORENCE MP	08/04/21	2.60	REVIEW AND EDIT DRAFT DECLARATIONS (2.0); CORRESPOND WITH CO-COUNSEL AND CLIENT RE: DOCUMENT REPOSITORY COMMUNICATION (0.6).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/05/21	3.20	CONFER WITH SKADDEN TEAM RE: KERP PROCESS (0.5); CONFER WITH CLIENT AND CO-COUNSEL IN PREPARATION FOR CALL WITH DOJ AND STATES RE: BANKRUPTCY ISSUE (0.5); PARTICIPATE IN CALL WITH DOJ AND STATES RE: BANKRUPTCY ISSUE (2.0); CORRESPOND WITH CO-COUNSEL RE: BANKRUPTCY PROCESS (0.2).
FLORENCE MP	08/06/21	1.30	REVIEW REVISIONS TO BANKRUPTCY MATERIAL (0.4); REVIEW AND ANALYZE MATERIALS RE: KERP PROGRAM (0.9).
FLORENCE MP	08/09/21	3.80	CORRESPOND WITH SKADDEN TEAM RE: KERP REVIEW (0.2); CONFER WITH P. FITZGERALD, J. BRAGG AND W. RIDGWAY RE: SAME (0.6); CORRESPOND WITH SKADDEN TEAM AND CO-COUNSEL RE: SAME (0.1); REVIEW AND ANALYZE MATERIALS RE: SAME (0.4); REVIEW CO-COUNSEL MEMOS RE: BANKRUPTCY PROCEDURE (0.5); REVIEW MEMO RE: CO-DEFENDANT CLAIMS (0.3); PARTICIPATE IN CALL WITH OUTSIDE COUNSEL AND CO-COUNSEL RE: BANKRUPTCY PROCEDURE (0.7); CONFER WITH CO-COUNSEL AND P. FITZGERALD RE: SAME (0.3); CONFER WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY (0.7).
FLORENCE MP	08/10/21	3.10	CONFER WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY (1.2); ATTEND SPECIAL COMMITTEE MEETING (1.4); REVIEW BANKRUPTCY HEARING TRANSCRIPT (0.5).
FLORENCE MP	08/11/21	0.50	CONFER WITH CLIENT AND CO-COUNSEL RE: KERP REVIEW (0.2); CORRESPOND WITH CLIENT RE: BANKRUPTCY ISSUE (0.3).
FLORENCE MP	08/12/21	3.50	CORRESPOND WITH SKADDEN TEAM RE: KERP REVIEW (0.3); ATTEND BANKRUPTCY HEARING (2.5); REVIEW BACKGROUND MATERIALS RE: BANKRUPTCY ISSUE (0.2); CONFER WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUE (0.4); FOLLOW UP WITH W. MCCONAGHA RE: SAME (0.1).
FLORENCE MP	08/13/21	3.00	ATTEND BANKRUPTCY HEARING (1.0); CORRESPOND WITH CO-COUNSEL RE: SAME (0.1); CORRESPOND WITH SKADDEN TEAM RE: KERP PROCESS (0.6); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY (1.0); FOLLOW UP CALL WITH CLIENT RE: SAME (0.3).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/15/21	0.60	CORRESPOND WITH CO-COUNSEL RE: BANKRUPTCY DISCOVERY (0.2); PARTICIPATE IN CALL WITH CO-COUNSEL RE: SAME (0.3); REVIEW DRAFT PLAN EDITS (0.1).
FLORENCE MP	08/16/21	1.60	ATTEND BANKRUPTCY HEARING (1.0); PARTICIPATE IN CALL WITH COUNSEL FOR CANADIAN CO-DEFENDANTS (0.6).
FLORENCE MP	08/17/21	3.00	CONFER WITH SKADDEN TEAM RE: SAME (0.5); CONFER WITH J. BRAGG RE: BANKRUPTCY ISSUE (0.1); ATTEND BANKRUPTCY HEARING (1.7); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUES (0.4); CORRESPOND WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.2).
FLORENCE MP	08/18/21	2.70	ATTEND BANKRUPTCY HEARING (1.2); CORRESPOND WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.1); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: DATA REPOSITORY (1.2); CORRESPOND WITH CO-COUNSEL RE: BANKRUPTCY ISSUES (0.2).
FLORENCE MP	08/19/21	3.80	CORRESPOND WITH CO-COUNSEL RE: KERP PROCESS (0.2); CORRESPOND WITH CO-COUNSEL RE: CO-DEFENDANT RELEASES (0.3); ATTEND BANKRUPTCY HEARING (1.5); CALL WITH CO-COUNSEL AND CONSULTANT RE: KERP PROCESS (0.4); CONFER WITH CO-COUNSEL RE: KERP PROCESS (0.6); CALL WITH SKADDEN TEAM RE: SAME (0.4); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.1); REVIEW AND COMMENT ON DRAFT MATERIAL RE: BANKRUPTCY (0.3).
FLORENCE MP	08/20/21	3.20	CONFER WITH SKADDEN TEAM AND CO-COUNSEL RE: KERP REVIEW (1.1); CORRESPOND WITH CO-COUNSEL RE: SAME (0.3); PARTICIPATE IN CALLS WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUES (1.8).
FLORENCE MP	08/22/21	0.90	PARTICIPATE IN CALL WITH CO-COUNSEL RE: KERP MOTION (0.9).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/23/21	5.60	CORRESPOND WITH CO-COUNSEL RE: KEIP PROCESS (0.2); CONFER WITH CO-COUNSEL AND SKADDEN TEAM RE: KERP PROCESS (0.2); ATTEND BANKRUPTCY HEARING (2.9); CONFER WITH CO-COUNSEL RE: SAME (0.4); DRAFT EMAIL RE: KERP PROCESS (1.1); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.1); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY ISSUE (0.3); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: SAME (0.3).
FLORENCE MP	08/24/21	3.10	PREPARE FOR SPECIAL COMMITTEE MEETING (0.2); ATTEND SPECIAL COMMITTEE MEETING (0.7); CORRESPOND WITH CLIENT RE: BANKRUPTCY ISSUES (0.1); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY REPOSITORY (0.2); CONFER WITH CLIENT AND CO-COUNSEL RE: SAME (1.0); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: EMERGENCE PLANNING (0.3); CONFER WITH CO-COUNSEL RE: KERP PROCESS (0.6).
FLORENCE MP	08/25/21	2.80	CONFER WITH SKADDEN TEAM RE: KERP PROCESS (1.0); CONFER WITH J. BRAGG AND W. MCCONAGHA RE: SAME (0.6); CORRESPOND WITH SKADDEN TEAM RE: SAME (1.0); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY HEARING (0.2).
FLORENCE MP	08/26/21	1.50	CONFER WITH DPW RE: KERP PROCESS (0.4); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.5); REVIEW BANKRUPTCY HEARING TRANSCRIPTS (0.6).
FLORENCE MP	08/27/21	2.40	CORRESPOND WITH SKADDEN TEAM RE: KERP PROCESS (0.4); PARTICIPATE IN CONFERENCE CALL WITH TEAM RE: SAME (0.8); REVIEW AND IDENTIFY MATERIALS RE: SAME (1.2).
FLORENCE MP	08/28/21	0.30	CORRESPOND WITH CO-COUNSEL RE: KERP PROCESS (0.3).
FLORENCE MP	08/30/21	0.10	CORRESPOND WITH SKADDEN TEAM RE: KERP PROCESS (0.1).
FLORENCE MP	08/31/21	0.20	CORRESPOND WITH CO-COUNSEL RE: KERP PROCESS (0.2).

59.20

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

RIDGWAY W	08/05/21	1.10	CONFER WITH SKADDEN TEAM RE: ANALYSIS FOR BANKRUPTCY ISSUE (0.5); ANALYZE HEARING TRANSCRIPT RE: BANKRUPTCY ISSUE (0.6).
RIDGWAY W	08/09/21	2.10	CONFER WITH SKADDEN TEAM RE: BANKRUPTCY AND KERP REVIEW (0.4); ANALYZE MATERIALS RE: KERP REVIEW (1.7).
RIDGWAY W	08/13/21	0.40	ANALYZE UPDATE RE: KERP ISSUES (0.4).
RIDGWAY W	08/17/21	0.30	ANALYZE KERP-RELATED ISSUES (0.3).
RIDGWAY W	08/19/21	0.50	CONFER WITH SKADDEN TEAM RE: KERP AND BANKRUPTCY-RELATED ISSUES (0.5).
RIDGWAY W	08/20/21	0.50	CONFER WITH SKADDEN TEAM RE: KERP REVIEW STRATEGY (0.5).
RIDGWAY W	08/22/21	0.70	CONFER WITH SKADDEN TEAM AND DPW RE: BANKRUPTCY SUBMISSION AND DOJ ISSUES (0.7).
RIDGWAY W	08/23/21	1.80	ANALYZE ISSUES RE: TRANSCRIPTS FOR KERP (1.1); CONFER WITH SKADDEN TEAM RE: KERP/KEIP (0.7).
RIDGWAY W	08/24/21	0.80	PARTICIPATE IN SPECIAL COMMITTEE MEETING RE: KERP ANALYSIS (0.5); CONFER WITH SKADDEN TEAM RE: STRATEGY FOR KERP REVIEW (0.3).
RIDGWAY W	08/25/21	2.00	CONFER WITH SKADDEN TEAM RE: KERP/KEIP REVIEW (1.1); CONFER WITH W. FIEBERG RE: PROCESS FOR REVIEW (0.4); ANALYZE MATERIALS RE: ASSIGNMENTS FOR REVIEW (0.5).
RIDGWAY W	08/26/21	0.40	CONFER WITH SKADDEN TEAM RE: STRATEGY FOR KEIP/KERP REVIEW (0.4).
RIDGWAY W	08/27/21	2.50	PREPARE PROCEDURES FOR KERP/KEIP REVIEW (0.7); CONFER WITH SKADDEN TEAM RE: KERP/KEIP REVIEW (0.9); PREPARE WORKPLAN FOR KEIP/KERP REVIEW (0.9).
RIDGWAY W	08/30/21	1.50	CONFER WITH C. HOUSTON RE: REVIEW (0.3); ANALYZE MATERIALS FOR KERP/KEIP REVIEW (1.2).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

RIDGWAY W	08/31/21	2.00	CONFER WITH C. HOUSTON AND S. PAULSON RE: KERP REVIEW (0.3); CONFER WITH SKADDEN TEAM RE: KERP REVIEW STRATEGY (0.6); REVIEW AND IDENTIFY MATERIALS FOR KERP REVIEW (1.1).
-----------	----------	------	--

16.60**Total Partner****164.20**

BEJAN WA	08/27/21	0.80	CALL WITH SKADDEN TEAM RE: KERP/KEIP WORKPLAN (0.8).
----------	----------	------	--

BEJAN WA	08/29/21	1.80	SEARCH FOR RELEVANT DOCUMENTS RE: KERP/KEIP WORKPLAN (1.8).
----------	----------	------	---

BEJAN WA	08/30/21	1.80	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KERP/KEIP WORKPLAN (1.8).
----------	----------	------	--

BEJAN WA	08/31/21	1.40	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KERP/KEIP WORKPLAN (1.4).
----------	----------	------	--

BEJAN WA	08/31/21	0.50	CALL WITH SKADDEN TEAM RE: KERP/KEIP WORKPLAN (0.5).
----------	----------	------	--

6.30

BERRY EL	08/27/21	0.80	SKADDEN TEAM CALL RE: ASSIGNMENT (0.8).
----------	----------	------	---

BERRY EL	08/30/21	3.90	REVIEW RELEVANT DOCUMENTS (3.9).
----------	----------	------	----------------------------------

BERRY EL	08/31/21	1.10	BEGIN TO DRAFT SUMMARIES (0.3); SKADDEN TEAM CALL RE: WORK PRODUCT (0.8).
----------	----------	------	---

5.80

CHAN AH	08/30/21	0.20	CONFER ON NEXT STEPS (0.2).
---------	----------	------	-----------------------------

CHAN AH	08/30/21	2.80	REVIEW MATERIALS FOR ISSUES OF INTEREST (2.8).
---------	----------	------	--

CHAN AH	08/31/21	0.90	CONFER ON NEXT STEPS (0.9).
---------	----------	------	-----------------------------

CHAN AH	08/31/21	1.30	REVIEW MATERIALS FOR ISSUES OF INTEREST (1.3).
---------	----------	------	--

5.20

HELLMAN E	08/26/21	0.10	CORRESPOND RE: WORK PRODUCT COLLECTION (0.1).
-----------	----------	------	---

HELLMAN E	08/27/21	0.80	CONFER WITH TEAM RE: KERP/KEIP (0.8).
-----------	----------	------	---------------------------------------

HELLMAN E	08/30/21	4.60	COLLECT WORK PRODUCT FOR DATABASE (4.6).
-----------	----------	------	--

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

HELLMAN E	08/31/21	1.70	COLLECT MATERIALS FOR DATABASE (1.7).
HELLMAN E	08/31/21	0.20	CONFER WITH A. CHAN RE: KERP/KEIP (0.2).
HELLMAN E	08/31/21	0.70	CONFER WITH TEAM RE: KERP/KIEP (0.7).
HELLMAN E	08/31/21	0.80	REVIEW MATERIAL RE: KERP/KEIP PROJECT (0.8).
8.90			
HOUSTON CD	08/05/21	3.60	ATTEND CALL WITH TEAM TO DISCUSS PROJECT (0.6); REVIEW BANKRUPTCY TRANSCRIPT (1.0); REVIEW FILES CONNECTING TO KEIP INDIVIDUALS (2.0).
HOUSTON CD	08/09/21	3.50	REVIEW FILES RELATED TO KERP INDIVIDUALS AT ISSUE (3.5).
HOUSTON CD	08/17/21	3.50	ATTEND CALL WITH TEAM (0.5); REVIEW DOCUMENTS IN AID OF ANALYZING KERP LIST (2.5); REVIEW CUSTOMER SERVICE FILES (0.5).
HOUSTON CD	08/18/21	0.30	ANALYZE KERP LIST (0.3).
HOUSTON CD	08/19/21	0.60	ATTEND CALL WITH COMMON INTEREST COUNSEL TO DISCUSS KERP ANALYSIS (0.6).
HOUSTON CD	08/20/21	1.10	ATTEND CALL WITH TEAM TO DISCUSS KERP ANALYSIS PROJECT (1.1).
HOUSTON CD	08/23/21	0.30	REVIEW DOCUMENTS RELATED TO KERP INDIVIDUALS (0.3).
HOUSTON CD	08/25/21	1.00	ATTEND CALL TO DISCUSS NEXT STEPS IN KERP PROJECT (1.0).
HOUSTON CD	08/27/21	1.30	ATTEND CALL WITH TEAM TO DISCUSS KERP PROCESS (0.8); REVIEW EMAILS IN AID OF KERP PROCESS (0.5).
HOUSTON CD	08/30/21	4.40	REVIEW PRIOR WORK PRODUCT IN AID OF KERP REVIEW (3.5); COMMUNICATE WITH FIRM PERSONNEL RE: KERP REVIEW (0.9).
HOUSTON CD	08/31/21	6.90	ATTEND CALLS WITH TEAM TO DISCUSS KERP PROJECT (1.2); REVIEW PRIOR WORK PRODUCT (5.7).

26.50

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

PAULSON SM	08/27/21	0.80	DISCUSS FACTUAL ISSUES RELATED TO BANKRUPTCY PROCEEDINGS WITH SKADDEN TEAM (0.8).
PAULSON SM	08/27/21	0.40	REVIEW DOCUMENTS RE: KERP REVIEW (0.4).
PAULSON SM	08/31/21	3.30	REVIEW AND ANALYZE FACTUAL ISSUES IN CONNECTION WITH BANKRUPTCY PROCEEDINGS (3.3).
PAULSON SM	08/31/21	0.90	CONDUCT CALL AND WEBEX WITH SKADDEN TEAM RE: ISSUES RELATED TO BANKRUPTCY (0.9).
		5.40	
Total Associate		58.10	
FIEBERG WR	08/25/21	0.60	DISCUSSIONS WITH PARTNER AND LEGAL TECHNOLOGY RE: DOCUMENT REVIEW FOR KERP/KEIP WORKPLAN (0.6).
FIEBERG WR	08/30/21	1.40	ASSIST WITH KERP/KEIP DOCUMENT COLLECTION (1.4).
FIEBERG WR	08/31/21	0.80	ASSIST WITH KERP/KEIP DOCUMENT COLLECTION (0.8).
		2.80	
Total Legal Assistant		2.80	
MATTER TOTAL		<u>225.10</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates
ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
Compliance Project

Bill Date: 10/15/21
Bill Number: 1869048

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/04/21	0.50	REVIEW AND EDIT LETTER (0.5).
BRAGG JL	08/05/21	0.60	CONFER WITH CO-COUNSEL AND CLIENT RE: COMPLIANCE MATTER (0.6).
BRAGG JL	08/06/21	1.50	EDIT AND FINALIZE LETTER (1.5).
BRAGG JL	08/12/21	0.30	CONFER WITH CLIENT RE: COMPLIANCE MATTER (0.3).
BRAGG JL	08/16/21	3.20	REVIEW AND EDIT LETTER (0.8); CONFER WITH CLIENT RE: COMPLIANCE MATTER (1.0); FOLLOW-UP WITH CLIENT RE: COMPLIANCE MATTER (0.8); PREPARE FOR CALL (0.6).
BRAGG JL	08/17/21	4.20	CONFER WITH CLIENT RE: COMPLIANCE MATTER (1.5); CONFER WITH CO-COUNSEL RE: COMPLIANCE MATTER (1.4); REVIEW AND ANALYSIS OF DOCUMENTS (0.9); CONFER WITH CLIENT RE: MATTER FOLLOW-UP (0.4).
BRAGG JL	08/18/21	1.60	CONFER WITH CO-COUNSEL RE: COMPLIANCE MATTER (0.8); REVIEW ADDITIONAL DATA RE: COMPLIANCE MATTER (0.8).
BRAGG JL	08/20/21	1.30	REVIEW AND ANALYZE MATERIAL (0.7); CONFER WITH CLIENT RE: COMPLIANCE MATTER (0.6).
		13.20	
FITZGERALD P	08/11/21	0.20	REVIEW AND RESPOND TO INTERNAL CORRESPONDENCE (0.2).
		0.20	
Total Partner		13.40	
BERRY EL	08/16/21	0.50	REVIEW LETTER (0.5).
BERRY EL	08/17/21	1.70	REVIEW AND REVISE LETTER (0.6); REVIEW MATERIAL (1.1).
BERRY EL	08/18/21	0.20	REVIEW SPREADSHEET (0.2).
		2.40	
Total Associate		2.40	
MATTER TOTAL		<u>15.80</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Corporate/Transactional AdviceBill Date: 10/15/21
Bill Number: 1869044

NAME	DATE	HOURS	DESCRIPTION
COYLE EM	08/13/21	1.00	CALL RE: TRANSACTIONAL ADVICE (1.0).
COYLE EM	08/17/21	0.20	CALL WITH MARSH RE: TRANSACTIONAL ADVICE (0.2).
		1.20	
FLORENCE MP	08/02/21	0.20	REVIEW DRAFT RECALL DOCUMENTATION (0.2).
FLORENCE MP	08/26/21	0.20	CORRESPOND WITH CLIENT RE: AGREEMENT (0.2).
		0.40	
MCCONAGHA W	08/02/21	0.50	FINALIZE EDITS ON AGREEMENT AND SUBMIT TO PURDUE FOR REVIEW (0.5).
MCCONAGHA W	08/02/21	1.00	REVIEW AND REVISE MATERIALS RE: TRANSACTIONAL ADVICE (1.0).
MCCONAGHA W	08/03/21	1.00	REVIEW OF TRANSACTIONAL MATERIALS (1.0).
MCCONAGHA W	08/03/21	1.00	WORK ON FINAL EDITS TO, AND REVIEW OF AGREEMENT (1.0).
MCCONAGHA W	08/04/21	0.50	EMAILS ON TRANSITION ISSUES (0.5).
MCCONAGHA W	08/04/21	0.50	ADDRESS QUESTIONS ARISING FROM REGULATORY CALL (0.5).
MCCONAGHA W	08/04/21	0.30	CALL WITH SKADDEN CO-COUNSEL RE: TRANSACTIONAL ISSUE (0.3).
MCCONAGHA W	08/04/21	0.30	CALL WITH CO-COUNSEL ON TRANSACTIONAL QUESTIONS (0.3).
MCCONAGHA W	08/04/21	0.50	CALL WITH OUTSIDE LEGAL TEAM RE: TRANSACTIONAL ISSUE (0.5).
MCCONAGHA W	08/05/21	1.00	CORRESPOND RE: TRANSACTIONAL ISSUES (1.0).
MCCONAGHA W	08/05/21	0.80	CALLS AND EMAILS WITH CO-COUNSEL ON REGULATORY TRANSITION ISSUES (0.8).
MCCONAGHA W	08/05/21	2.30	REVIEW ON TRANSACTIONAL ISSUE MATERIALS (1.3); CORRESPOND RE: SAME (1.0).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

MCCONAGHA W	08/06/21	0.50	EMAILS RE: TRANSITION ISSUES (0.5).
MCCONAGHA W	08/08/21	1.50	REVIEW AND SUMMARIZE UPDATES TO AGREEMENT (1.5).
MCCONAGHA W	08/08/21	0.30	EMAILS RE: TRANSACTIONAL ISSUE (0.3).
MCCONAGHA W	08/09/21	1.00	CONFER WITH SKADDEN CO-COUNSEL ON AGREEMENT (1.0).
MCCONAGHA W	08/09/21	1.80	DRAFT AND REFINE PRESENTATION RE: TRANSACTIONAL ISSUES (1.8).
MCCONAGHA W	08/09/21	2.50	CORRESPOND RE: TRANSACTIONAL ADVICE (2.5).
MCCONAGHA W	08/09/21	2.00	CALLS WITH CO-COUNSEL AND OUTSIDE COUNSEL, RE: TRANSACTIONAL ISSUES (2.0).
MCCONAGHA W	08/09/21	3.30	CORRESPOND RE: TRANSACTIONAL ADVICE (3.3).
MCCONAGHA W	08/10/21	2.00	PREPARE FOR AND PARTICIPATE IN SPECIAL COMMITTEE CALL (2.0).
MCCONAGHA W	08/10/21	2.30	REVIEW AND UPDATE AGREEMENT (1.3); CONFER WITH SKADDEN TEAM RE: SAME (1.0).
MCCONAGHA W	08/10/21	2.50	REVIEW AND UPDATE TRANSACTIONAL MATERIAL (1.5); CONFER WITH SKADDEN TEAM RE: SAME (1.0).
MCCONAGHA W	08/10/21	0.50	EMAILS ON MEETING RE: TRANSITION (0.5).
MCCONAGHA W	08/11/21	1.50	WORK ON UPDATES RE: AGREEMENT (1.5).
MCCONAGHA W	08/11/21	0.50	CALL WITH CO-COUNSEL RE: TRANSITION DOCUMENTS (0.5).
MCCONAGHA W	08/11/21	0.50	CORRESPOND RE: TRANSITION ISSUES (0.5).
MCCONAGHA W	08/11/21	2.00	REVIEW AND REVISE UPDATED TRANSACTIONAL MATERIALS (2.0).
MCCONAGHA W	08/11/21	0.50	REVIEW AND REVISE TALKING POINTS FOR CALL (0.5).
MCCONAGHA W	08/12/21	0.50	REVIEW UPDATED TRANSACTIONAL MATERIAL (0.5).
MCCONAGHA W	08/12/21	0.50	CALL WITH CO-COUNSEL ON TRANSITION ISSUES (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

MCCONAGHA W	08/12/21	0.50	REVIEW DOCUMENTS FROM CO-COUNSEL ON TRANSITION ISSUES (0.5).
MCCONAGHA W	08/12/21	0.50	CORRESPOND RE: MEETING (0.5).
MCCONAGHA W	08/13/21	1.00	PARTICIPATE IN MEETING WITH FDA AND TEAM MEMBERS RE: REGULATORY ISSUES (1.0).
MCCONAGHA W	08/13/21	0.30	CONFER WITH CO-COUNSEL RE: REGULATORY ISSUES (0.3).
MCCONAGHA W	08/13/21	0.50	CORRESPOND WITH CO-COUNSEL RE: REGULATORY ISSUE (0.5).
MCCONAGHA W	08/13/21	1.30	PREPARE FOR MEETING WITH FDA (1.3).
MCCONAGHA W	08/16/21	1.00	REVIEW REGULATORY AND COMPLIANCE MATERIALS (1.0).
MCCONAGHA W	08/16/21	1.50	RESEARCH AND REVIEW TRANSACTIONAL ISSUES (1.5).
MCCONAGHA W	08/16/21	0.80	REVIEW REGULATORY MATERIAL (0.8).
MCCONAGHA W	08/17/21	0.80	PREPARE FOR AND PARTICIPATE IN CALL ON REGULATORY ISSUE (0.8).
MCCONAGHA W	08/17/21	1.00	PREPARE FOR CALL RE: REGULATORY ISSUE (0.5); CALL WITH CLIENT RE: SAME (0.5).
MCCONAGHA W	08/17/21	0.80	REVIEW LEGAL RESEARCH ON TRANSACTIONAL ISSUE (0.8).
MCCONAGHA W	08/17/21	0.80	CONFER WITH CO-COUNSEL ON REGULATORY TRANSITION ISSUES (0.8).
MCCONAGHA W	08/18/21	2.00	DRAFT OUTLINE RE: REGULATORY SUBMISSION (2.0).
MCCONAGHA W	08/18/21	0.40	EMAILS WITH CO-COUNSEL RE: TRANSITION ISSUE (0.4).
MCCONAGHA W	08/19/21	0.80	REVIEW OF MATERIALS RE: TRANSACTIONAL ISSUES (0.8).
MCCONAGHA W	08/20/21	1.30	UPDATE OUTLINE RE: REGULATORY TRANSITION ISSUES (1.3).
MCCONAGHA W	08/20/21	0.80	CORRESPOND RE: TRANSITION ISSUES (0.8).
MCCONAGHA W	08/20/21	1.00	PREPARE FOR AND PARTICIPATE IN CALL WITH OUTSIDE COUNSEL AND CO-COUNSEL ON TRANSACTIONAL ISSUE (1.0).
MCCONAGHA W	08/23/21	0.50	CORRESPOND RE: TRANSACTIONAL ADVICE (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

MCCONAGHA W	08/23/21	0.80	CORRESPOND WITH CO-COUNSEL RE: AGREEMENT (0.8).
MCCONAGHA W	08/23/21	1.00	FINALIZE DRAFT MATERIALS RE: REGULATORY ISSUES (1.0).
MCCONAGHA W	08/23/21	0.50	CALL WITH CO-COUNSEL ON TRANSITION WORKSTREAMS (0.5).
MCCONAGHA W	08/23/21	0.80	RESEARCH ON REGULATORY ISSUES (0.8).
MCCONAGHA W	08/24/21	1.30	CORRESPOND RE: TRANSITION ISSUES (1.3).
MCCONAGHA W	08/24/21	0.50	REVIEW MATERIAL FOR CALL WITH CO-COUNSEL RE: TRANSACTIONAL ISSUE (0.5).
MCCONAGHA W	08/24/21	0.50	CORRESPOND RE: TRANSACTIONAL ADVICE (0.5).
MCCONAGHA W	08/25/21	0.50	REVIEW LEGAL ISSUES LIST AND PREPARE FOR CALL ON SAME WITH CO-COUNSEL (0.5).
MCCONAGHA W	08/25/21	1.80	LEGAL ANALYSIS OF TRANSACTIONAL ISSUE (1.8).
MCCONAGHA W	08/25/21	2.30	DRAFT LETTER ON TRANSITION QUESTIONS (2.3).
MCCONAGHA W	08/25/21	0.50	CALL WITH CLIENT RE: TRANSACTIONAL ADVICE (0.5).
MCCONAGHA W	08/26/21	0.80	REVISE LETTER RE: REGULATORY ISSUE (0.8).
MCCONAGHA W	08/26/21	0.80	EMAILS AND RESEARCH RE: TRANSITION ISSUES (0.8).
MCCONAGHA W	08/26/21	0.50	EMAILS ON TRANSITION ISSUES (0.5).
MCCONAGHA W	08/26/21	0.50	CONFER WITH CO-COUNSEL ON TRANSITION ISSUES (0.5).
MCCONAGHA W	08/27/21	0.50	CONFER WITH CO-COUNSEL ON TRANSACTIONAL ISSUES (0.5).
MCCONAGHA W	08/27/21	2.30	REVIEW AND REVISE TEMPLATE; COORDINATE WITH CO-COUNSEL ON SAME (2.3).
MCCONAGHA W	08/27/21	0.50	UPDATE LETTER RE: REGULATORY ISSUE (0.5).
MCCONAGHA W	08/27/21	1.00	CALL WITH CLIENT RE: CHANGE OF CONTROL ISSUES (1.0).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

MCCONAGHA W	08/30/21	0.50	CORRESPOND WITH FDA RE: TRANSITION ISSUE (0.5).
MCCONAGHA W	08/30/21	0.50	CORRESPOND WITH CO-COUNSEL ON RE: TRANSITION ISSUE (0.5).
MCCONAGHA W	08/30/21	0.50	CONFER RE: TRANSACTIONAL ISSUE (0.5).
MCCONAGHA W	08/30/21	1.00	CALL WITH TEAM ON TRANSACTIONAL ISSUES (1.0).
MCCONAGHA W	08/31/21	0.40	CORRESPOND WITH FDA RE: TRANSITION ISSUES (0.4).
MCCONAGHA W	08/31/21	3.00	REVIEW AND REVISE AGREEMENT TEMPLATE (3.0).
MCCONAGHA W	08/31/21	0.50	EMAIL WITH CLIENT RE: TRANSITION ISSUES (0.5).
MCCONAGHA W	08/31/21	0.50	CALL WITH CO-COUNSEL ON TRANSACTIONAL ISSUES (0.5).

77.80

SCHLOSSBERG RK	08/03/21	0.60	ATTENTION TO TRANSACTION-RELATED MATTERS (0.6).
SCHLOSSBERG RK	08/08/21	0.60	REVIEW TRANSACTION-RELATED DOCUMENTS (0.6).

1.20**Total Partner 80.60**

BERRY EL	08/11/21	0.10	CALL WITH W. MCCONAGHA RE: WORK PRODUCT (0.1).
BERRY EL	08/12/21	2.70	REVIEW AND SUMMARIZE CONTRACT (2.7).

2.80

CHAN AH	08/02/21	1.70	REVISE DRAFT CORRESPONDENCES AND TALKING POINTS (1.7).
CHAN AH	08/04/21	0.10	REVIEW ASSESSMENT (0.1).
CHAN AH	08/10/21	0.10	REVIEW AGREEMENT MARK UP (0.1).

1.90

ICKES KR	08/01/21	1.60	REVISE AGREEMENT (1.6).
ICKES KR	08/03/21	0.70	REVIEW AND REVISE AGREEMENT (0.7).
ICKES KR	08/08/21	1.30	REVIEW CHANGES TO AGREEMENT AND DRAFT ISSUES LIST (1.3).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

ICKES KR	08/09/21	2.30	PREPARE FOR AND ATTEND CALL WITH CLIENT TO DISCUSS TRANSACTIONAL ADVICE (0.6); REVIEW AND REVISE TRANSACTIONAL MATERIAL (1.7).
ICKES KR	08/10/21	2.80	REVIEW AND REVISE TRANSACTIONAL MATERIAL (2.8).
ICKES KR	08/11/21	0.40	REVISE AND FINALIZE TRANSACTIONAL MATERIAL (0.4).
ICKES KR	08/23/21	0.90	REVISE AGREEMENT (0.9).
ICKES KR	08/27/21	1.20	CONFER WITH SKADDEN TEAM RE: TRANSACTIONAL MATERIAL (0.5); REVIEW TRANSACTIONAL MATERIAL (0.7).

11.20**Total Associate 15.90****MATTER TOTAL 96.50**

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates
ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
DOJ

Bill Date: 10/15/21
Bill Number: 1869039

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/03/21	2.60	PARTICIPATE IN WEEKLY PRINCIPALS CALL (1.0); DISCUSSION WITH SKADDEN TEAM RE: DOJ ISSUES (0.5); DISCUSSION WITH CO-COUNSEL RE: DOJ ISSUES (1.1).
BRAGG JL	08/04/21	0.70	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.7).
BRAGG JL	08/05/21	0.90	STRATEGY CALL WITH CO-COUNSEL RE: DOJ ISSUES (0.6); CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.3).
BRAGG JL	08/16/21	1.00	BOARD CALL (1.0).
BRAGG JL	08/17/21	1.60	CONFER WITH CO-COUNSEL RE: HEARING-RELATED DOJ ISSUES (1.6).
BRAGG JL	08/18/21	2.00	LISTEN TO DOJ RELATED PARTS OF HEARING (2.0).
BRAGG JL	08/19/21	2.50	LISTEN TO DOJ RELATED BANKRUPTCY PROCEEDINGS (1.8); CALL WITH CO-COUNSEL RE: DOJ MATTERS (0.7).
BRAGG JL	08/20/21	1.00	WEEKLY SKADDEN DOJ MEETING (1.0).
BRAGG JL	08/23/21	0.50	CALL WITH CLIENT AND CO-COUNSEL RE: DOJ ISSUES (0.5).
BRAGG JL	08/24/21	1.40	ATTEND WEEKLY PRINCIPALS CALL (0.8); CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.6).
BRAGG JL	08/26/21	3.10	ATTENTION TO DOJ ISSUES (0.9); CALL WITH CO-COUNSEL RE: DOJ ISSUES (0.5); CONFER WITH CO-COUNSEL RE: PRIVILEGE ISSUES (0.4); CONFER WITH CLIENT RE: DOJ ISSUES (0.5); CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.8).
BRAGG JL	08/27/21	2.40	STRATEGY DISCUSSION RE: DOJ ISSUES (1.0); CONFER WITH CO-COUNSEL RE: DOJ STRATEGY ISSUES (1.4).
BRAGG JL	08/29/21	3.30	REVIEW AND EDIT LETTERS RE: DOJ REVIEW (3.3).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BRAGG JL	08/31/21	1.80	PARTICIPATE IN PRINCIPALS CALL (1.0); CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.4); CONFER WITH CO-COUNSEL RE: DOJ STRATEGY ISSUES (0.4).
		24.80	
FITZGERALD P	08/02/21	0.30	REVIEW AND COMMENT ON DRAFT FILING (0.3).
FITZGERALD P	08/03/21	3.30	CORRESPONDENCE WITH CLIENT RE: STATUS (0.2); REVIEW DRAFT FILING (0.2); REVIEW DOJ REQUEST (0.4); PARTICIPATE IN WEEKLY PRINCIPALS CALL (1.0); CONFER WITH DOJ RE: REQUEST (0.4); UPDATE CALL WITH AND SKADDEN TEAM RE: DOJ REQUESTS AND ISSUES (0.5); CALL WITH SPECIAL COMMITTEE, OUTSIDE COUNSEL, CLIENT AND SKADDEN RE: DOJ MATTERS (0.4); ORGANIZE RE: DOCUMENT REVIEW (0.2).
FITZGERALD P	08/04/21	3.80	CONFER WITH CLIENT, CO-COUNSEL AND J. BRAGG RE: DOJ MATTERS (0.8); CONFER WITH M. FLORENCE, CO-COUNSEL AND J. BRAGG RE: DOJ MATTERS (0.6); REVIEW AND EDIT DRAFT FACTUAL DOCUMENT (1.6); REVIEW DRAFT FILING (0.7); CORRESPOND WITH DOJ (0.1).
FITZGERALD P	08/05/21	0.80	STRATEGY CALL WITH CO-COUNSEL AND SKADDEN (0.5); CONFER WITH SKADDEN TEAM RE: STRATEGY CALL (0.2); REVIEW MATERIALS RE: DOJ (0.1).
FITZGERALD P	08/06/21	1.20	REVIEW DRAFT MATERIALS RE: DOJ POSITION (1.2).
FITZGERALD P	08/09/21	3.00	REVIEW LETTER TO DOJ (0.2); REVIEW DOJ REQUEST (0.2); COORDINATION WITH OTHER COMPANY COUNSEL RE: PURDUE POSITION (0.3); STRATEGY AND UPDATE CALL WITH M. FLORENCE, AND OUTSIDE COUNSEL (0.7); FOLLOW UP CALL WITH M. FLORENCE, OUTSIDE COUNSEL (0.6); SYNTHESIZE LEGAL ANALYSIS RE: DOJ ISSUE (1.0).
FITZGERALD P	08/10/21	0.40	REVIEW LEGAL ANALYSIS (0.4).
FITZGERALD P	08/10/21	0.80	UPDATE CALL WITH CO-COUNSEL AND SKADDEN (0.2); ATTEND WEEKLY PRINCIPALS CALL (0.6).
FITZGERALD P	08/11/21	0.20	UPDATE WITH M. FLORENCE RE: DOJ REQUEST (0.1); RESPONSE TO DOJ (0.1).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	08/13/21	0.10	CALL WITH DOJ AND M. FLORENCE RE: DOJ REQUEST (0.1).
FITZGERALD P	08/17/21	0.10	CONSULTATION WITH M. FLORENCE (0.1).
FITZGERALD P	08/19/21	1.40	DOJ UPDATE CALL WITH CO-COUNSEL AND SKADDEN (0.9); RESPOND TO CLIENT INQUIRIES (0.3); FOLLOW-UP RESEARCH (0.2).
FITZGERALD P	08/20/21	0.40	CALL WITH DOJ ATTORNEYS AND M. FLORENCE RE: DISCOVERY ISSUE (0.2); CONFER WITH M. FLORENCE RE: SAME (0.1); UPDATE CALL WITH CLIENT RE: DOJ CONVERSATION (0.1).
FITZGERALD P	08/23/21	1.00	ATTENTION TO ISSUES AT CONFIRMATION HEARING (0.8); CONFER WITH M. FLORENCE RE: CONFIRMATION HEARING ISSUES (0.2).
FITZGERALD P	08/24/21	1.10	CALL WITH DOJ AND M. FLORENCE RE: DISCOVERY ISSUE (0.2); CALL WITH M. FLORENCE AND CO-COUNSEL RE: SAME (0.1); ATTEND WEEKLY PRINCIPALS CALL (0.8).
FITZGERALD P	08/25/21	0.50	CONFER WITH M. FLORENCE RE: DOJ REQUESTS (0.2); UPDATE WITH CO-COUNSEL RE: DOJ ISSUES (0.2); CONFER WITH M. FLORENCE RE: DOJ REQUESTS (0.1).
FITZGERALD P	08/26/21	4.60	UPDATE CALL WITH CO-COUNSEL (0.3); UPDATE CALL WITH CLIENT AND CO-COUNSEL RE: DOJ ISSUES (0.8); COORDINATION CALL WITH CO-COUNSEL (0.2); INTERNAL SKADDEN CALL RE: FOLLOW UP ON DOJ ISSUES (0.9); DRAFT OUTLINE RE: DOJ ISSUES (2.4).
FITZGERALD P	08/27/21	9.10	REVIEW MATERIALS AS BACKGROUND FOR CALL WITH DOJ (0.7); CALL WITH DOJ (0.3); UPDATE CALL WITH CLIENT, CO-COUNSEL AND SKADDEN TEAM (0.8); ANALYZE MATERIAL RE: DOJ ISSUES (6.0); FOLLOW-UP CALL WITH DOJ (0.2); UPDATE WITH CO-COUNSEL (0.2); CONFER WITH CLIENT AND CO-COUNSEL RE: CASE STATUS (0.7); CONFER WITH M.FLORENCE RE: SAME (0.2).
FITZGERALD P	08/28/21	5.50	DRAFT STATEMENT OF COMPANY POSITION (5.5).
FITZGERALD P	08/29/21	1.70	REVIEW AND EDIT STATEMENT OF COMPANY POSITION (1.7).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	08/30/21	0.30	CONFER WITH J. BRAGG (0.1); CONFER WITH J. BENTIVOGLIO (0.2).
FITZGERALD P	08/31/21	1.80	REVIEW MATERIALS (0.1); ATTEND WEEKLY PRINCIPALS CALL (1.1); CONFER WITH W. RIDGWAY AND J. BRAGG RE: DOJ ISSUES (0.3); CONFER WITH CO-COUNSEL, W. RIDGWAY AND J. BRAGG RE: DOJ ISSUES (0.3).
41.40			
FLORENCE MP	08/02/21	0.60	CONFER WITH CO-COUNSEL AND OUTSIDE COUNSEL RE: DOCUMENT DATABASE (0.6).
FLORENCE MP	08/03/21	2.50	PARTICIPATE IN WEEKLY PRINCIPALS CALL WITH CLIENT AND CO-COUNSEL (1.0); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: DOJ STATUS (0.9); CONFER WITH CLIENT AND J. BRAGG RE: DOJ ISSUES (0.6).
FLORENCE MP	08/04/21	1.30	CONFER WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ STATUS (0.8); REVIEW AND EDIT DRAFT PRESS STATEMENT (0.5).
FLORENCE MP	08/05/21	1.40	CALL WITH CO-COUNSEL, AND SKADDEN TEAM RE: DOJ STATUS (0.5); CONFER WITH SKADDEN TEAM RE: SAME (0.4); CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.5).
FLORENCE MP	08/06/21	0.70	CONFER WITH J. BRAGG RE: DOJ ISSUES (0.4); CONFER WITH A. DUNN RE: SAME (0.3).
FLORENCE MP	08/09/21	0.20	REVIEW MATERIALS RE: PRESS REPORT (0.2).
FLORENCE MP	08/10/21	1.00	CORRESPOND WITH E. HELLMAN RE: DOCUMENT REVIEW (0.1); CONFER WITH CO-COUNSEL RE: DOJ ISSUE (0.2); PARTICIPATE IN WEEKLY PRINCIPALS CALL WITH CLIENT AND CO-COUNSEL (0.7).
FLORENCE MP	08/11/21	1.70	CORRESPOND WITH DOJ AND CO-COUNSEL RE: DOJ REQUESTS (0.3); CONFER WITH CO-COUNSEL AND E. HELLMAN RE: DOCUMENT REVIEWS (0.5); CONFER WITH CO-COUNSEL AND CLIENT RE: DOJ DOCUMENT REQUEST (0.7); CORRESPOND WITH OUTSIDE COUNSEL RE: PRIVILEGE REVIEW (0.2).
FLORENCE MP	08/12/21	0.20	CORRESPOND WITH CO-COUNSEL RE: DOJ REVIEW STATUS (0.2).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/13/21	0.80	CONFER WITH CO-COUNSEL RE: PREP FOR CALLS WITH DOJ (0.4); PARTICIPATE IN CALL WITH DOJ RE: DOCUMENT REQUEST (0.2); PARTICIPATE IN CALL WITH DOJ RE: DOCUMENT PRODUCTIONS (0.2).
FLORENCE MP	08/16/21	1.00	REVIEW AND COMMENT ON PRIVILEGED DOCUMENTS (0.4); ATTEND MEETING (0.6).
FLORENCE MP	08/17/21	0.40	CORRESPOND WITH CO-COUNSEL AND E. HELLMAN RE: PRIVILEGE REVIEW (0.4).
FLORENCE MP	08/18/21	0.40	CORRESPOND WITH CLIENT AND SKADDEN TEAM RE: DOJ MATERIALS (0.4).
FLORENCE MP	08/19/21	0.90	CONFER WITH CO-COUNSEL, P. FITZGERALD AND J. BRAGG RE: MATTER STATUS (0.9).
FLORENCE MP	08/20/21	0.40	PARTICIPATE IN CALL WITH DOJ RE: DOCUMENT PRODUCTION (0.2); CONFER WITH P. FITZGERALD RE: SAME (0.2).
FLORENCE MP	08/23/21	0.40	CONFER WITH CO-COUNSEL, P. FITZGERALD AND J. BRAGG RE: DOJ REQUEST (0.4).
FLORENCE MP	08/24/21	1.30	CONFER WITH DOJ RE: DISCOVERY ISSUE (0.2); FOLLOW UP WITH P. FITZGERALD AND CO-COUNSEL RE: SAME (0.2); ATTEND WEEKLY PRINCIPALS CALL (0.9).
FLORENCE MP	08/25/21	0.70	CONFER WITH CO-COUNSEL RE: DOJ REQUESTS (0.3); CONFER WITH P. FITZGERALD RE: SAME (0.3); PARTICIPATE IN CALL WITH DOJ RE: SAME (0.1).
FLORENCE MP	08/26/21	0.40	CORRESPOND WITH CLIENT RE: DOJ REQUEST (0.2); PARTICIPATE IN CALL WITH DOJ AND CO-COUNSEL RE: SAME (0.2).
FLORENCE MP	08/27/21	0.90	CONFER WITH CLIENT AND CO-COUNSEL RE: CASE STATUS (0.7); CONFER WITH P. FITZGERALD RE: SAME (0.2).
FLORENCE MP	08/28/21	0.40	CORRESPOND WITH CO-COUNSEL RE: DOJ MATTER STATUS (0.4).
FLORENCE MP	08/29/21	0.80	CORRESPOND WITH CO-COUNSEL RE: DOJ MATTER STATUS (0.8).
FLORENCE MP	08/30/21	0.10	CORRESPOND WITH SKADDEN TEAM AND CO-COUNSEL RE: MATTER STATUS (0.1).

18.50

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

RIDGWAY W	08/04/21	0.40	CONFER WITH SKADDEN TEAM RE: DOJ MATTERS (0.4).
RIDGWAY W	08/05/21	0.60	CONFER WITH CLIENT AND SKADDEN TEAM RE: DOJ AND BANKRUPTCY STRATEGY (0.6).
RIDGWAY W	08/10/21	2.00	CONFER WITH CO-COUNSEL, AND SKADDEN TEAM RE: DOJ STRATEGY (0.4); PARTICIPATE IN PRINCIPAL'S MEETING (0.7); CONFER WITH J. BERMAN RE: RESEARCH (0.3); ANALYZE RESEARCH RE: DOJ ISSUES (0.6).
RIDGWAY W	08/11/21	0.50	ANALYZE RESEARCH RE: DOJ ISSUES (0.5).
RIDGWAY W	08/26/21	0.50	CONFER WITH SKADDEN TEAM RE: DOJ ISSUES (0.5).
RIDGWAY W	08/27/21	2.10	CONFER WITH CLIENT AND SKADDEN TEAM RE: DOJ STRATEGY (0.8); CONFER WITH CO-COUNSEL, SKADDEN TEAM, AND CLIENT RE: DOJ STRATEGY (0.8); REVIEW RESEARCH RE: DOJ MATTER (0.5).
RIDGWAY W	08/29/21	0.30	REVIEW MATERIALS RE: DOJ ISSUE (0.3).
RIDGWAY W	08/30/21	0.60	CONFER WITH CLIENT RE: DOJ ISSUES (0.6).
RIDGWAY W	08/31/21	1.90	PARTICIPATE IN PRINCIPALS MEETING RE: DOJ STRATEGY (1.0); CONFER WITH P. FITZGERALD AND J. BRAGG RE: DOJ STRATEGY (0.5); CONFER WITH CO-COUNSEL, P. FITZGERALD, AND J. BRAGG RE: DOJ STRATEGY (0.4).

8.90**Total Partner****93.60**

BEJAN WA	08/11/21	0.30	PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (0.3).
----------	----------	------	---

0.30

BERMAN JH	08/10/21	2.90	CONDUCT RESEARCH RE: DOJ ISSUES (2.9).
-----------	----------	------	--

2.90

HELLMAN E	08/06/21	0.30	COORDINATE PRIVILEGE REVIEW FOR EXTERNAL PRODUCTION (0.3).
-----------	----------	------	--

HELLMAN E	08/09/21	0.30	COORDINATE PRIVILEGE REVIEW OF EXTERNAL PRODUCTION (0.3).
-----------	----------	------	---

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

HELLMAN E	08/10/21	0.90	CONDUCT PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (0.9).
HELLMAN E	08/10/21	0.40	COORDINATE PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (0.4).
HELLMAN E	08/11/21	4.00	CONDUCT PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (4.0).
HELLMAN E	08/11/21	0.20	CONFER WITH M. FLORENCE RE: PRIVILEGE REVIEW (0.2).
HELLMAN E	08/11/21	1.40	COORDINATE PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (1.4).
HELLMAN E	08/12/21	3.70	CONDUCT PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (3.7).
HELLMAN E	08/13/21	8.10	CONDUCT PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (8.1).
HELLMAN E	08/14/21	2.70	CONDUCT PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (2.7).
HELLMAN E	08/15/21	0.60	SUMMARIZE PRIVILEGE REVIEW FINDINGS (0.6).
HELLMAN E	08/16/21	0.80	CONDUCT PRIVILEGE REVIEW RE: EXTERNAL PRODUCTION (0.8).
HELLMAN E	08/17/21	0.70	COORDINATE RE: PRIVILEGE AND EXTERNAL PRODUCTION (0.7).
HELLMAN E	08/19/21	0.10	DRAFT CORRESPONDENCE RE: EXTERNAL PRODUCTION (0.1).
		24.20	
Total Associate		27.40	
FIEBERG WR	08/18/21	2.10	PREPARE BINDERS OF DOCUMENTS (2.1).
		2.10	
Total Legal Assistant		2.10	
MATTER TOTAL		<u>123.10</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates
ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

Purdue Pharma L.P.
General Advice

Bill Date: 10/15/21
Bill Number: 1869038

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/03/21	1.20	CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUES (0.5); CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUES (0.7).
BRAGG JL	08/06/21	0.50	CONFER WITH CO-COUNSEL RE: REGULATORY COMPLIANCE ISSUES (0.5).
BRAGG JL	08/11/21	1.10	CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUES (0.5); CONFER WITH CO-COUNSEL RE: REGULATORY COMPLIANCE ISSUES (0.6).
BRAGG JL	08/12/21	0.60	CONFER WITH CO-COUNSEL AND CLIENT RE: REGULATORY COMPLIANCE ISSUES (0.6).
BRAGG JL	08/13/21	1.00	CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUES (0.6); CONFER WITH CO-COUNSEL RE: REGULATORY COMPLIANCE ISSUES (0.4).
BRAGG JL	08/16/21	1.00	CONFER WITH CO-COUNSEL RE: REGULATORY COMPLIANCE ISSUES (0.4); REVIEW AND ANALYSIS OF REGULATORY COMPLIANCE ISSUE (0.6).
BRAGG JL	08/18/21	0.60	CONFER WITH CO-COUNSEL RE: VARIOUS REGULATORY AND COMPLIANCE ISSUES (0.6).
BRAGG JL	08/20/21	1.10	CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUES (0.7); CONFER WITH CO-COUNSEL RE: REGULATORY COMPLIANCE ISSUES (0.4).
BRAGG JL	08/24/21	0.60	REVIEW MATERIALS IN PREPARATION FOR CLIENT CALL (0.6).
BRAGG JL	08/25/21	1.50	PREPARE FOR CLIENT CALL TO DISCUSS DATA ISSUES (0.5); CALL WITH CLIENT RE: DATA ISSUES (1.0).
BRAGG JL	08/26/21	0.80	CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUE (0.8).
BRAGG JL	08/27/21	1.10	STRATEGY DISCUSSION WITH CLIENT RE: REGULATORY ISSUES (1.1).

11.10

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	08/11/21	0.60	REVIEW MEMO RE: REGULATORY COMPLIANCE QUESTION (0.2); CORRESPOND WITH SKADDEN TEAM AND CO-COUNSEL RE: SAME (0.4).
FLORENCE MP	08/12/21	1.40	CORRESPOND WITH J. BRAGG AND CLIENT RE: REGULATORY COMPLIANCE ISSUE (0.4); CONFER WITH CLIENT RE: REGULATORY COMPLIANCE ISSUE (0.6); CORRESPOND WITH J. BRAGG AND CLIENT RE: SAME (0.4).
FLORENCE MP	08/13/21	0.20	CORRESPOND WITH J. BRAGG AND CO-COUNSEL RE: REGULATORY COMPLIANCE ISSUE (0.2).
FLORENCE MP	08/16/21	0.20	CONFER WITH J. BRAGG AND CO-COUNSEL RE: REGULATORY COMPLIANCE QUESTION (0.2).
FLORENCE MP	08/18/21	0.70	CONFER WITH J. BRAGG RE: REGULATORY COMPLIANCE MATTERS (0.5); CORRESPOND WITH CLIENT RE: SAME (0.2).
FLORENCE MP	08/20/21	0.90	PARTICIPATE IN CALL WITH CLIENT RE: REGULATORY COMPLIANCE ISSUE (0.9).
FLORENCE MP	08/25/21	1.20	PARTICIPATE IN CALL WITH J. BRAGG AND CLIENT RE: DATA (1.0); CONFER WITH J. BRAGG RE: STATUS OF REGULATORY COMPLIANCE MATTERS (0.2).
FLORENCE MP	08/26/21	0.80	CONFER WITH CLIENT AND J. BRAGG RE: REGULATORY COMPLIANCE MATTERS (0.8).
FLORENCE MP	08/27/21	1.10	CALL WITH CLIENT AND J. BRAGG RE: REGULATORY COMPLIANCE MATTERS (1.1).
		7.10	
Total Partner		18.20	
DUNN AM	08/11/21	0.50	PARTICIPATE ON CALL WITH CLIENT (0.5).
		0.50	
Total Counsel		0.50	
MATTER TOTAL		<u>18.70</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
General ComplianceBill Date: 10/15/21
Bill Number: 1869050

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/04/21	0.50	CALL WITH CLIENT AND CO-COUNSEL RE: REVIEW (0.5).
BRAGG JL	08/11/21	0.40	CONFER WITH CO-COUNSEL RE: REGULATORY CONSULTING ISSUES (0.4).
BRAGG JL	08/30/21	0.70	NEGOTIATE TERMS OF ENGAGEMENT LETTER (0.4); CONFER WITH CO-COUNSEL RE: TERMS OF ENGAGEMENT LETTER (0.3).
		1.60	
FLORENCE MP	08/05/21	0.50	CONFER WITH A. DUNN AND E. BLOUSTEIN RE: CONSULTANT ENGAGEMENT LETTER AND EDIT SAME (0.5).
		0.50	
Total Partner		2.10	
DUNN AM	08/04/21	0.60	DRAFT SUMMARY RE: COMPLIANCE ISSUE (0.6).
DUNN AM	08/05/21	0.30	CONFER RE: ENGAGEMENT LETTER (0.2); MAKE REVISIONS RE: SAME (0.1).
DUNN AM	08/11/21	1.00	REVIEW ENGAGEMENT LETTER (1.0).
DUNN AM	08/22/21	0.60	REVISE ENGAGEMENT LETTER (0.6).
DUNN AM	08/30/21	0.50	PARTICIPATE ON CALL RE: ENGAGEMENT LETTER (0.5).
DUNN AM	08/30/21	0.20	PARTICIPATE ON CALL RE: ENGAGEMENT LETTER (0.2).
DUNN AM	08/30/21	0.90	ATTEND TO ISSUES RE: ENGAGEMENT LETTER (0.9).
		4.10	
Total Counsel		4.10	
MATTER TOTAL		<u>6.20</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Healthcare Law ComplianceBill Date: 10/15/21
Bill Number: 1869056

NAME	DATE	HOURS	DESCRIPTION
DUNN AM	08/12/21	1.40	PARTICIPATE ON CLIENT CALL RE: HEALTHCARE POLICIES (0.5); REVIEW POLICY OUTLINE (0.9).
DUNN AM	08/16/21	3.90	BENCHMARK AND REVISE HEALTHCARE COMPLIANCE POLICY (3.9).
DUNN AM	08/27/21	2.40	REVISE HEALTHCARE COMPLIANCE POLICY (2.4).
DUNN AM	08/31/21	6.30	REVISE HEALTHCARE POLICY (6.3).
		14.00	
Total Counsel		14.00	
CHAN AH	08/11/21	0.30	CONFER ON POLICY UPDATE (0.3).
CHAN AH	08/11/21	0.10	DISCUSS NEXT STEPS RE: POLICY UPDATE (0.1).
CHAN AH	08/13/21	1.50	DRAFT POLICY UPDATE (1.5).
CHAN AH	08/16/21	1.80	DRAFT POLICY UPDATE (1.8).
CHAN AH	08/17/21	0.50	DRAFT POLICY UPDATE (0.5).
CHAN AH	08/18/21	5.60	DRAFT POLICY UPDATE (5.6).
CHAN AH	08/20/21	3.30	DRAFT POLICY UPDATE (3.3).
CHAN AH	08/30/21	4.40	DRAFT POLICY UPDATE (4.4).
CHAN AH	08/31/21	2.70	WORK ON POLICY UPDATE (2.7).
		20.20	
Total Associate		20.20	
MATTER TOTAL		<u>34.20</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Litigation Discovery IssuesBill Date: 10/15/21
Bill Number: 1869045

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/31/21	0.50	CONFER WITH CO-COUNSEL RE: LITIGATION DISCOVERY ISSUES (0.5).
		0.50	
MCCONAGHA W	08/02/21	0.50	REVIEW UPDATED MATERIALS FROM CLIENT (0.5).
MCCONAGHA W	08/03/21	0.50	CALL WITH CLIENT RE: LITIGATION DISCOVERY ISSUES (0.5).
MCCONAGHA W	08/18/21	2.30	DRAFT AND REVISE LETTER (2.3).
MCCONAGHA W	08/19/21	1.00	CALL WITH CLIENT RE: LETTER (1.0).
MCCONAGHA W	08/19/21	1.30	DRAFT AND REVISE LETTER (1.3).
MCCONAGHA W	08/19/21	0.50	FINAL RESEARCH AND ANALYSIS ON POLICIES RE: LITIGATION DISCOVERY ISSUES (0.5).
MCCONAGHA W	08/20/21	1.30	WORK ON LETTER (1.3).
MCCONAGHA W	08/23/21	0.80	REVIEW AND REVISE DRAFT LETTER (0.8).
MCCONAGHA W	08/24/21	0.80	CALLS WITH CLIENT ON UPDATE (0.8).
MCCONAGHA W	08/24/21	0.80	REVISE LETTER (0.8).
MCCONAGHA W	08/24/21	0.50	CORRESPOND RE: UPDATE (0.5).
MCCONAGHA W	08/25/21	1.50	REVISE UPDATE LETTER (1.0); CORRESPOND RE: SAME (0.5).
MCCONAGHA W	08/30/21	1.00	DRAFT LEGAL ANALYSIS RE: LITIGATION DISCOVERY ISSUES (1.0).
MCCONAGHA W	08/30/21	1.00	REVISE LETTER (1.0).
MCCONAGHA W	08/31/21	0.50	REVISE LETTER (0.5).
MCCONAGHA W	08/31/21	0.30	CORRESPOND WITH CO-COUNSEL RE: LETTER (0.3).
		14.60	
Total Partner		15.10	
MATTER TOTAL		<u>15.10</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Managed Care ReviewBill Date: 10/15/21
Bill Number: 1869049

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	08/02/21	0.40	CONFER WITH CLIENT RE: STATUS AND NEXT STEPS (0.4).
BRAGG JL	08/30/21	0.70	REVIEW AND EDIT MEMO (0.7).
BRAGG JL	08/31/21	0.50	CONFER WITH CO-COUNSEL RE: LEGAL ISSUES (0.5).
		1.60	
FLORENCE MP	08/02/21	0.40	CONFER WITH CLIENT AND J. BRAGG RE: MATTER STATUS (0.4).
FLORENCE MP	08/31/21	0.20	REVIEW DRAFT MEMO AND CORRESPOND WITH CO-COUNSEL RE: SAME (0.2).
		0.60	
Total Partner		2.20	
DUNN AM	08/23/21	3.30	DRAFT MEMO (3.3).
DUNN AM	08/30/21	0.50	FINALIZE MEMORANDUM (0.5).
		3.80	
Total Counsel		3.80	
MATTER TOTAL		<u>6.00</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Project CatalystBill Date: 10/15/21
Bill Number: 1869046

NAME	DATE	HOURS	DESCRIPTION
FLORENCE MP	08/17/21	0.30	CONFER WITH CO-COUNSEL RE: REGULATORY ISSUE (0.3).
FLORENCE MP	08/18/21	0.40	CALL WITH CLIENT AND CO-COUNSEL RE: REGULATORY ISSUE (0.4).
		0.70	
GIBSON ML	08/24/21	0.30	CORRESPOND WITH WORKING GROUP RE: REVIEW OF QUESTIONS POSED BY CLIENT (0.3).
GIBSON ML	08/26/21	0.50	ATTENTION TO DRAFT SUMMARY RE: CLIENT QUESTION (0.5).
GIBSON ML	08/27/21	0.50	MULTIPLE CORRESPONDENCE WITH WORKING GROUP RE: MATTERS RELATING TO EMERGENCE FROM BANKRUPTCY AND CLIENT QUESTION (0.5).
GIBSON ML	08/31/21	1.50	REVIEW AGREEMENTS AND ANALYSIS OF CLIENT QUESTION (1.5).
		2.80	
SCHLOSSBERG RK	08/19/21	0.20	CONFER RE: TRANSACTION-RELATED MATTERS (0.2).
SCHLOSSBERG RK	08/24/21	0.40	CONFER WITH SKADDEN TEAM MEMBERS (0.4).
SCHLOSSBERG RK	08/24/21	0.50	REVIEW TRANSACTION-RELATED DOCUMENTS (0.5).
SCHLOSSBERG RK	08/25/21	0.20	CONFER WITH SKADDEN TEAM MEMBERS (0.2).
		1.30	
Total Partner		4.80	
ICKES KR	08/24/21	3.70	DRAFT SUMMARY RE: PROJECT CATALYST ISSUE (3.7).
		3.70	
LEE J	08/25/21	1.40	ANALYSIS RE: PROJECT CATALYST ISSUE (1.4).
		1.40	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

YUH C	08/25/21	3.30	REVIEW CATALYST TRANSACTION DOCUMENTS (3.3).
YUH C	08/26/21	3.90	CONTINUE TO REVIEW CATALYST TRANSACTION DOCUMENTS (3.9).
		7.20	
Total Associate		12.30	
MATTER TOTAL		<u><u>17.10</u></u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Project ChimeraBill Date: 10/15/21
Bill Number: 1869055

NAME	DATE	HOURS	DESCRIPTION
SCHLOSSBERG RK	08/13/21	0.20	COORDINATE TRANSACTION RELATED MATTERS (0.2).
		0.20	
Total Partner		0.20	
ICKES KR	08/16/21	1.10	DRAFT OVERVIEW EMAIL AND COMPILE DOCUMENTS (1.1).
		1.10	
Total Associate		1.10	
MATTER TOTAL		<u>1.30</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Retention/Fee MatterBill Date: 10/15/21
Bill Number: 1869042

NAME	DATE	HOURS	DESCRIPTION
CLARK AW	08/02/21	0.60	WORK ON SUPPLEMENTAL DISCLOSURE ISSUE (0.3); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.3).
CLARK AW	08/03/21	0.70	CALL WITH L. SPIEGEL, P. FITZGERALD, J. MADDEN RE: SUPPLEMENTAL DISCLOSURE ISSUE (0.5); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.2).
CLARK AW	08/04/21	0.40	REVIEW FEE EXAMINER REPORT (0.2) AND RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.2).
CLARK AW	08/06/21	0.40	WORK ON DISCLOSURE ISSUES (0.1); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.1); CALL WITH SKADDEN TEAM (0.2).
CLARK AW	08/09/21	1.30	WORK ON SUPPLEMENTAL DISCLOSURE ISSUES (0.2); REVIEW RELATED COURT PAPERS (0.8); CONFER WITH G. PANAGAKIS (0.3).
CLARK AW	08/13/21	0.60	WORK ON ISSUES RELATED TO RESPONSE TO FEE EXAMINER REPORT (0.3); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.3).
CLARK AW	08/16/21	1.30	PREPARE FOR HEARING RE: INTERIM FEE APPLICATION (0.6); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.3) AND RELATED COURT PAPERS (0.4).
CLARK AW	08/19/21	1.20	WORK ON SUPPLEMENTAL DISCLOSURE ISSUES (1.0); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.2).
CLARK AW	08/20/21	1.70	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURE (1.1); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.6).
CLARK AW	08/21/21	1.40	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURES (0.6); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.3); CALL WITH SKADDEN TEAM (0.5).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

CLARK AW	08/22/21	0.80	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURES (0.3); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.2); CONFER WITH J. LARKIN (0.3).
CLARK AW	08/23/21	0.70	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURE (0.4); REVIEW CORRESPONDENCE WITH SKADDEN TEAM (0.3).
CLARK AW	08/24/21	0.80	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURE (0.5); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.3).
CLARK AW	08/25/21	1.10	WORK ON SUPPLEMENTAL DISCLOSURE (0.7); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.4).
CLARK AW	08/26/21	2.60	WORK ON SUPPLEMENTAL DISCLOSURE ISSUES (0.9); REVIEW RELATED COURT PAPERS (0.7) AND CORRESPONDENCE WITH SKADDEN TEAM (0.3); ANALYSIS RE: ISSUE RAISED BY COURT (0.7).
CLARK AW	08/27/21	0.50	WORK ON SUPPLEMENTAL DISCLOSURE ISSUES (0.3); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.2).
		16.10	
FITZGERALD P	08/03/21	0.40	CONFER WITH SKADDEN TEAM (0.4).
FITZGERALD P	08/13/21	0.20	ATTENTION TO FEE EXAMINER INQUIRY (0.2).
		0.60	
FLORENCE MP	08/10/21	0.50	REVIEW AND EDIT PRE-BILL (0.5).
FLORENCE MP	08/20/21	0.20	CORRESPOND RE: BANKRUPTCY BUDGET (0.2).
FLORENCE MP	08/24/21	0.40	CORRESPOND WITH CO-COUNSEL RE: MATTER BUDGETS (0.4).
FLORENCE MP	08/26/21	0.10	CORRESPOND WITH SKADDEN TEAM RE: BUDGETS (0.1).
		1.20	
Total Partner		17.90	
BAILEY MS	08/12/21	0.50	CALL WITH J. MADDEN AND B. DEAN RE: FEE APPLICATION PROCESS (0.4); EMAILS WITH M. FLORENCE RE: SAME (0.1).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL

		0.50	
Total Counsel		0.50	
DEAN B	08/04/21	3.40	REVISE FEE STATEMENT MATERIALS (3.4).
DEAN B	08/11/21	4.30	REVISE FEE STATEMENT MATERIALS (4.3).
DEAN B	08/12/21	0.50	CALL WITH M. BAILEY AND J. MADDEN RE: BILLING PROCESS (0.5).
DEAN B	08/13/21	2.00	REVISE FEE STATEMENT MATERIALS (2.0).
DEAN B	08/15/21	0.80	REVISE FEE STATEMENT MATERIALS (0.8).
DEAN B	08/31/21	1.00	IMPLEMENT REVISIONS TO FEE STATEMENT MATERIALS (1.0).
		12.00	
MADDEN J	08/03/21	1.40	CALL WITH TEAM RE: UPDATED DISCLOSURES AND FOLLOW UP RE: SAME (0.5); REVIEW FEE EXAMINER REPORT AND CONSIDER RESPONSE RE: SAME (0.9).
MADDEN J	08/12/21	0.50	CALL WITH TEAM RE: PREPARATION OF FEE MATERIALS AND FOLLOW UP RE: SAME (0.5).
MADDEN J	08/13/21	0.80	ANALYSIS (0.4) AND COMMUNICATIONS WITH FEE EXAMINER AND TEAM RE: FEE EXAMINER REPORT (0.4).
MADDEN J	08/16/21	0.90	REVIEW (0.3) AND CORRESPONDENCE (0.4) RE: FEE ORDER AND SETTLEMENT; FOLLOW UP RE: SAME (0.2).
MADDEN J	08/19/21	0.40	ANALYSIS RE: DISCLOSURES (0.4).
MADDEN J	08/20/21	0.50	FURTHER ANALYSIS RE: DISCLOSURES (0.5).
MADDEN J	08/30/21	2.00	REVIEW/REVISE FEE STATEMENT MATERIALS (2.0).
		6.50	
O'HARE WS	08/26/21	0.80	PREPARE FEE APPLICATION MATERIALS (0.8).
		0.80	
Total Associate		19.30	
MATTER TOTAL		<u>37.70</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Rhodes CompaniesBill Date: 10/15/21
Bill Number: 1869047

NAME	DATE	HOURS	DESCRIPTION
MCCONAGHA W	08/11/21	0.50	REVIEW MATERIALS RE: REGULATORY ISSUE (0.3); DRAFT EMAIL FOR CLIENT ON SAME (0.2).
MCCONAGHA W	08/11/21	0.50	CALL WITH CLIENT RE: REGULATORY ISSUE (0.5).
MCCONAGHA W	08/12/21	1.80	REVIEW AGREEMENT (0.8); DRAFT SUMMARY EMAIL FOR CO-COUNSEL RE: SAME (1.0).
MCCONAGHA W	08/12/21	0.30	CORRESPOND WITH CO-COUNSEL RE: LETTER REVISIONS (0.3).
MCCONAGHA W	08/17/21	0.30	CALL WITH CLIENT ON DEA ISSUE (0.3).
MCCONAGHA W	08/17/21	1.50	LEGAL RESEARCH AND REVIEW OF RELATED MATERIALS RELATED TO DEA ISSUES (1.5).
MCCONAGHA W	08/18/21	0.50	PREPARE FOR CALL RE: DEA ENGAGEMENT (0.2); PARTICIPATE IN CALL WITH CO-COUNSEL RE: SAME (0.3).
		5.40	
Total Partner		5.40	
MATTER TOTAL		<u>5.40</u>	

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIALPurdue Pharma L.P.
Various Texas ActionsBill Date: 10/15/21
Bill Number: 1869041

NAME	DATE	HOURS	DESCRIPTION
BOYLE J	08/02/21	0.80	REVIEW AND ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (0.8).
BOYLE J	08/16/21	1.30	REVIEW AND ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (1.3).
BOYLE J	08/23/21	1.10	REVIEW AND ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (1.1).
BOYLE J	08/24/21	2.10	REVIEW AND ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (2.1).
BOYLE J	08/25/21	0.50	REVIEW AND ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (0.5).
BOYLE J	08/30/21	0.50	REVIEW AND ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (0.5).
		6.30	
Total Counsel		6.30	
REDMAN R	08/02/21	0.70	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.5).
REDMAN R	08/03/21	0.40	ANALYZE INCOMING FILINGS (0.1); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.3).
REDMAN R	08/04/21	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY FOR PURDUE LITIGATION (0.7).
REDMAN R	08/05/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	08/06/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	08/09/21	0.60	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.4).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

**ATTORNEY WORK PRODUCT
PRIVILEGED AND CONFIDENTIAL**

REDMAN R	08/10/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	08/11/21	0.70	ANALYZE INCOMING FILINGS (0.2); ORGANIZE PLEADINGS AND DISCOVERY (0.5).
REDMAN R	08/12/21	0.90	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	08/16/21	1.00	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.8).
REDMAN R	08/17/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	08/18/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	08/19/21	0.90	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	08/20/21	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	08/23/21	0.70	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.5).
REDMAN R	08/24/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	08/25/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS (0.6).
REDMAN R	08/26/21	1.00	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.8).
REDMAN R	08/27/21	0.70	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.5).
REDMAN R	08/30/21	0.90	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	08/31/21	0.90	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).

Skadden, Arps, Slate, Meagher & Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

17.00

Total Legal Assistant

17.00

MATTER TOTAL

23.30

EXHIBIT E

EXPENSE DETAIL

skadden, arps, slate, meagher & flom llp and affiliates

Purdue Pharma L.P.
DOJ

Bill Date: 10/15/21
Bill Number: 1869039

Disbursement	Date	Vendor/Employee/Dept.	Amount
Messengers/ Courier	08/18/21	Federal Express Corp.	<u>31.30</u>
		TOTAL MESSENGERS/ COURIER	\$31.30
		TOTAL MATTER	\$31.30